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(NA).!However,! frequent! development! of! resistance! and!unpredictable! toxicity! are!
crucial! drawbacks! of! these! compounds.! Some! of! the!main! resistance!mechanisms!
against! NAs! include! limited! cellular! permeability! and! decreased! initial!
phosphorylation!of!the!NAs,!thus!limiting!the!concentration!of!active!NAs!inside!the!
target! cells.! The! ProTide! approach! is! a! pronucleotide! technology! that! successfully!
overcomes!these!drawbacks!by!releasing!the!monophosphorylated!NA! into!the!cell!
and!has!led!to!multiple!clinical!candidate!drugs.!
This! work! was! focussed! on! the! application! of! the! ProTide! approach! to!
different! anticancer! NAs! with! the! aim! of! improving! their! performance! and!
pharmacological! properties.! These! NAs! were! 2"chlorocordycepin,! 3’"
ethynylnucleosides!and!the!novel!NA!3"N4"ethenogemcitabine.!!
A! new! and! efficient! synthesis! for! 2"chlorocordycepin! was! developed,! and!
three! synthetic! routes! to! obtain! its! ProTides! were! explored.! This! family! of!




5Tmethyluridine.! In!addition,! a! small! family!of!novel!ProTides! for!each!of! these!3’T
ethynylnucleosides!was!prepared.!
Finally,!3"N4"ethenogemcitabine,! a! novel! NA! originating! from! the! fusion! of!
gemcitabine! and! 3,N4Tdeoxycytidine,! was! designed! and! synthesised.! The! ProTide!




nucleosides.! Enzymatic! assays! and! docking! studies! were! performed! to! gain!
understanding!of!the!pronucleotides’!activation!processes.!Finally,!the!fluorescence!
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also! spread! to!other! regions!of! the!body! through!metastasis,!which!causes!90%!of!
cancer!associated!deaths.2!Major!treatment!modalities!include!surgery,!radiotherapy!
and! chemotherapy.3! However,! other! new! strategies! such! as! immunotherapy,!
thermal! therapy,! photodynamic! therapy,! and! stem! cell! transplants,! have! emerged!
recently.4!
Nucleosides!and!nucleotides!are!endogenous!compounds!involved!in!several!
cellular!processes.!Their!key! role! is!DNA!and!RNA!synthesis,! cell! signalling,!enzyme!
regulation!and!metabolism.5!They!take!part!in!essential!processes,! including!energy!
provision!(ATP),!protein!synthesis!and!cell!replication.!
Nucleoside! and! Nucleotide! analogues! (NA)! are! chemically! modified!
compounds! developed! to! mimic! their! physiological! counterparts.5! Currently! their!
main!applications!exploit!their!antiviral!and!antiTcancer!activity.!The!British!National!
Formulary!shows!14!NAs!among!the!92!approved!drugs!used!in!antiTcancer!therapy!
(Table# 1.1).6! Some! of! these! NA! are! core! to! cancer! chemotherapy! and! considered!









Capecitabine! Adjuvant! treatment! following! surgery! for! stage! III! (Dukes'! C)! colon!
cancer.!
Cladribine! Hairy! cell! leukaemia! and! chronic! lymphocytic! leukaemia! in! patients!






Fludarabine!! Advanced! BTcell! chronic! lymphocytic! leukaemia,! or! after! firstTline!
treatment!in!patients!with!sufficient!boneTmarrow!reserves.!









AntiTcancer!NAs!are!designed! to! interfere!with! the! function!of! endogenous!
nucleosides!by!exploiting!the!same!metabolic!pathways.!They!can!potentially!target!
any! of! the! involved! enzymes! or! biochemical! processes,! from! the! cellular! uptake!









Most! often,! antiTcancer! NAs! are! inactive! prodrugs! that! depend! on!
intracellular! phosphorylation! to! reach! their! nucleoside! phosphate! forms!
(nucleotides),! most! frequently! triphosphates,! which! are! the! active! species! with!
biological!effects.9 
There! are! two! processes! for! the! cell! to! acquire! nucleotides:! the! de# novo!
synthesis! pathway! and! the! salvage! pathway.! The! de# novo! pathway! involves! the!
synthesis! of! ribonucleotides! from! small! molecules.! Ribonucleotides! can! then! be!
transformed! into! deoxyribonucleotides! by! reduction! of! the! 2’Thydroxyl! group! by!
ribonucleotide!reductase! (RR).!The!salvage!pathway! is! the! transport!of!nucleosides!
into! the! cell! and! their! subsequent! phosphorylation! (Figure! 1.1).! NAs! exploit! both!
pathways!to!exert!their!intracellular!effects.!
!
The! salvage! pathway! depends! on! the! specific! nucleoside! transporters,!
specifically! concentrative! nucleoside! transporters! (CNTs)! and! equilibrative!
nucleoside! transporters! (ENTs).! CNTs! perform! an! energy! dependant! (active)!




step! at! position! 5’! of! the! sugar! moiety! which! is! catalysed! by! riboT! or!







in! the! enzyme,! and! by! 5’! nucleotidase! (5’TNT),! which! cleaves! the!monophosphate!
moiety,!thus!again!releasing!the!free!nucleoside.!
Second! and! third! nucleotide! phosphorylations! are! reversible!
phosphorotransferase! reactions! performed! by! nucleotide! monophosphate! kinase!
and! nucleotide! diphosphate! kinase,! to! obtain! the! active! nucleotide! triphosphate!
(NTP).!




the!synthesis!of!DNA!and!RNA,!or!by!negative! feedback! regulation!of! the!enzymes!
involved!in!the!synthesis!of!endogenous!nucleotide!triphosphates.!!
!
Figure' 1.2' Mechanism# of# activation# of# most# NAs# (Figure# by# Jordheim# et# al.,#






Despite! the! numerous! approved! antiTcancer! NAs,! some! of! their!
pharmacological! characteristics! still! need! to!be! improved.! The!main! issues! are! the!
development!of!resistance!and!side!effects!such!as!delayed!unspecific!toxicity.!




Resistance!of!NA!therapy! linked!to! insufficient! intracellular!concentration!of!
the!triphosphate!species!of!the!NA!is!largely!reported.!This!is!due!to!either!inefficient!





















The! development! of! new! NAs! is! being! driven! by! the! need! to! overcome!
resistance! and! efficacy! issues.! This! means! that! the! NA! has! to! achieve! sufficient!
concentration!of!its!active!form!inside!the!cell!to!efficiently!induce!apoptosis.!Some!
developed! strategies! to! achieve! this! goal! include! the! synthesis! of! new! NAs! with!
changes! on! their! sugar! or! base! moieties,! liposomal! formulations,! orally!
administrated!formulations,!and!nucleotide!prodrugs:!pronucleotides.5!
!Strategies!aiming!to!increase!the!concentration!of!active!5’TNA!triphosphates!
inside! the! cell! seek! to! bypass! the! two! major! limiting! steps:! transportTdependent!
intracellular!uptake,!and!the!first!phosphorylation!step.!Pronucleotides!are!designed!
to!get! inside!of! the!cell! through!passive!diffusion!across! the!membrane,!and,!once!
















The! SATE! approach! consists! of! symmetric! pronucleotides! bearing! STacylT2T
thioethyl!(SATE)!groups!as!esteraseTlabile!phosphate!protecting!groups.!This!strategy!
has! been! applied! to! phosphate! and! phosphonate! drugs,! especially! in! antiviral!
therapy.! Some! studies! for! the! treatment! of! hepatitis! B! virus! with! derivatives! of!
acyclovir!showed!better!results!of!the!SATE!analogue!than!the!parent!nucleoside13.!
In! its!phosphonate!form!it!was!applied!to!adefovir! for!treatment!of!HIV,! leading!to!
better!activity!than!the!parent!nucleoside.14!
The!moieties!of!SATE!pronucleotides!are!hydrolysed!by!nonspecific!esterases,!
leading! to! an! unstable! 2Tthioethyl! intermediate.! This! intermediate! is! then! quickly!
cleaved,!releasing!the!2Tthioethyl!moiety!as!an!episulfide!as!well!as!the!mono!SATE!






























































































(POM)! or! diisopropyloxycarbonyloxymethyl! ester! (POC)! groups! to! mask! the!
phosphate.! This! strategy! was! successfully! applied! to! nucleoside! phosphonate!
prodrugs,!leading!to!the!approved!agents!Hepsera!(bisTPOM!of!adefovir)!and!Viread!
(bisTPOC! of! tenofovir),! both! of! which! are! used! for! the! treatment! of! hepatitis! B!
infections.! They! get! enzymatically! activated! by! unspecific! esterases.! Despite! the!
structural! similarity! BisTPOC! and! BisTPOM! follow! slightly! different! activation!
pathways.! When! bisTPOC! interacts! with! an! esterase,! the! terminal! isopropyl! is!
cleaved,! leading! to! a! carboxylate! intermediate! that! delivers! the! monoTPOC!
compound! by! chemical! rearrangement.! In! contrast,! in! the! esteraseTmediated!
activation! of! POM,! the! entire! terminal! ester! is! cleaved! (pivalic! acid),! after! which!
rearrangement!delivers!the!monoTPOM!compound.!The!mono!POC!and!mono!POM!
compounds!then!either!undergo!an!activation!second!cycle!or!are!being!cleaved!by!








































































































cyclic! bifunctionality! that! integrates! the! two! hydroxyl! residues! in! the! phosphate!
group.!The!release!of!the!NA!inside!the!cell!is!driven!by!pH:!in!acid!conditions!(pH!<!
7),18!the!PTO!bond!at!5’!of!the!nucleoside!is!broken,!opening!the!cycle!and!followed!
by!spontaneous!CTO!cleavage!of! the!salicyl!alcohol! (Scheme!1.4).! 19!Changes! in! the!








1,3Tpropanyl! esters! in! the! phosphate! moiety.! The! activation! of! this! prodrug! is!
accomplished!via!cytochrome!P450Tcatalyzed!oxidation,!resulting!in!the!intracellular!
release! of!monophosphate!NAs! in! hepatocytes! (Scheme! 1.5).21! This! approach!was!
designed! to! specifically! target! hepatotropic! virus! infections.! HepDirect! of! 2′TCT
methylcytidine! (a! viral! polymerase! inhibitor)! increased! the! concentration! of! the!




This! approach! was! also! applied! to! the! phosphonate! drug! adefovir! leading! to!

































nucleotide! is! forming! a! 6Tmembered! ring! with! the! 3’! hydroxyl! group! of! the!
nucleotide.!In!this!way,!one!of!the!hydroxyl!groups!in!the!phosphate!group!is!being!
masked.!The!remaining!hydroxyl!group!of!the!phosphate!moiety!is!bound!to!an!alkyl!
moiety.! The! prodrug! is! activated! by! dealkylation! of! the! phosphate! group! via!
cytochrome!P450.!Then,!a!phosphodiesterase!enzyme!releases!the!hydroxyl!group!at!






! This! strategy! aims! to! introduce! the! NAs! into! the! cell! by! mimicking!
lysophosphatidylcholine,! replacing! the! choline! of! the! natural! substrate! by! the!
nucleotide! analogue! (Scheme! 1.7).! The! prodrug! is! being! intracellularly! released! as!
monophosphate! NA! by! the! action! of! lysophospholipase! C.17! Of! note,! unlike! the!
previously! reported! approaches,! only! one! hydroxyl! group! of! the! phosphate! is!
masked.!This!approach!led!to!CMX!157,!a!prodrug!of!tenofovir!for!the!treatment!of!
Hepatitis!B!which!is!currently!undergoing!phase!2!clinical!studies,27!and!brincidofovir,!

























































This! category! developed! by! Professor! Chris! McGuigan! and! coTworkers! is!
covered! in! detail! in! chapter! 2.! There! are! three! main! generations! in! the!
phosphoramidate! family.! The! first! two! generations! were! developed! in! the! early!
nineteen!nineties.!The!phosphorodiamidates!were!the!first!of!these!compounds!that!
















































o =  O Phosphorodiamidate
o =  C Phosphonodiamidates
o =  O Aryloxy phosphoramidate
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A! ProTide! is! a! prodrug! of! a! monophosphorylated! NA.! The! charge! of! the!
phosphate!group!(which!is!dissociated!at!physiological!pH)!is!masked!with!an!aryloxy!
group!bound!to! the!phosphate!by!a!phosphoester!bond,!and!an!ester!of!an!amino!
acid! moiety! (usually! a! natural! LTamino! acid)! bound! to! the! phosphate! by! a!
phosphoramidate! bond.! Those! moieties! improve! the! cellular! uptake! of! the!





The! history! of! the! ProTides! started! in! the! early! 1990s.! Professor! Chris!
McGuigan! and! coTworkers! were! working! on! introducing! monophosphorylated!
nucleotide! analogues! into! the! cells! by! masking! the! negative! charges! of! the!
phosphate!group!with!different!groups.!They!aimed!for!groups!that!would!allow!the!







derivatives.! Those! compounds! enhanced! the! activity! of! vidarabine! (antiviral)! and!





azidothymidine! (AZT)! and! 2’,! 3’Tdideoxycytidine! (ddCyd),! and! despite! numerous!
tested! modifications! very! poor! activity! was! observed! compared! to! their! parent!
nucleosides.!1,4!!
By! focusing! on! improving! the! activity! of! AZT,! McGuigan! and! colleagues!
investigated!alternative!masking! groups! to! further! facilitate! intracellular! release!of!
the! nucleotides.! They! substituted! one! of! the! (halo)! alkyl! esters! for! an! amino! acid!
ester!(aaTester),!creating!the!first!alkyloxy!phosphoramidates.5!These!new!compound!
showed!an!increased!activity!compared!to!the!previously!explored!dialkyl!phosphate!
prodrugs! of! AZT.! Over! the! next! year,! they! introduced! a! second! amino! acid! ester!




reach! the! triphosphate! form! and! thus! did! not! exert! activity! due! to! lack! of! initial!
phosphorylation,! the! phosphorodiamidate! bypassed! the! kinaseTdependent!
activation!and!exhibited!high!antiviral!activity.!Structure!activity!relationship!studies!
on! both! alkyl! phosphoramidate! and! phosphorodiamidate! approaches! showed! the!




At! the! same! time,! McGuigan! and! colleagues! investigated! the! impact! of!
substituting!the!alkyl!ester!groups!of!the!alkyl!phosphate!triester!with!aryl!moieties.!
Some!of! these!diaryl!phosphate!prodrugs! improved!the!antiTHIV!activity!of!AZT! for!
the! first! time.7,8! However,! despite! their! potency,! these! drugs! did! not! bypass! the!
phosphorylation!step.!They!were!prodrugs!of!AZT!and!delivered!the!nucleoside!more!
efficiently!into!the!cells,!but!they!did!not!release!the!5´Tmonophosphate!form.9!
Therefore,! the! high! activity! of! aryloxy! nucleosides! was! combined! with! the!
capability!of!the!phosphoramidates!to!bypass!kinaseTdependent!activation,!thereby!





compounds! were! active! in! cell! lines! where! AZT! had! acquired! resistance.10! Those!
studies! identified! phenyl! methoxyalanilyl! substituents! as! those! with! the! highest!
antiviral!activity,!performing!100!times!better!than!AZT.!This!strategy!has!then!been!
widely!applied!by!McGuigan!and!coTworkers!and!other!groups!to!develop!approved!




Another!modification! of! the! phosphoramidate! approach!was! to! apply! it! to!
acyclic! nucleoside! phosphonates! as! tenofovir! or! adefovir.12! Nucleoside!
phosphonates! are! nucleotides! linked! to! the! phosphate! group! through! a! PTC! bond.!
This! strategy! aims! to! deliver! the! monophosphate! species! into! the! cells! and! to!
provide!resistance!to!enzymatic!dephosphorylation.!However,! their!main!drawback!
is!again!cellular!uptake!because!of!the!negatively!charged!phosphonate!moiety.!For!
Tenofovir,! the! first! strategy!was! to!mask! the! hydroxyl! groups! of! the! phosphonate!








and! osteoTtoxic! effects! caused! by! high! plasma! levels! of! tenofovir,! other!
pronucleotide!forms!were!investigated!and!the!aryloxy!phosphonamidate!approach!
was! applied.! Tenofovir! alafenamide! showed! a! 90%! reduction! in! plasma! tenofovir!
concentration!and! lower!toxicity! in!clinical! trials,13!which! led!to! its!approval!by! the!
FDA!in!2015.!!
!! The!bulk!of!this!thesis!is!focused!on!the!ProTide!approach!and!its!anticancer!
application,! except! when! promising! biological! results! stimulated! further! research!
into!other!prodrug!approaches!as!in!the!case!of!chapter!4.!!
ProTides9as9anticancer9agents9
To!date,! three!ProTides!have!undergone! clinical! trials! as! anticancer! agents:!
NUCT1031,!NUCT3370!and!Thymectacin.!!
NUCT1031! is! a! ProTide! of! gemcitabine.! Gemcitabine! is! an! anticancer! agent!
used!in!the!treatment!of!different!solid!tumours,!and!especially!in!the!treatment!of!
pancreatic!cancer,!where! it! is!the!current!first! line!drug.! It! interferes!with!different!
cellular! functions! leading! to! apoptosis.! The! major! mechanism! for! its! anticancer!
activity! is! the! incorporation! into! the! DNA! during! the! replication! process! where! it!
replaces! deoxycytidine,! but! other! synergies! are! reported! as! well! (chapter! 6).! All!
mechanisms!described! in! the! literature! involve! at! the! very! least! the! conversion!of!
the!unphosphorylated!drug!to!the!monophosphorylated!form.!Resistance!to!the!drug!
has!been!mainly!attributed!to!the!low!plasma!membrane!permeability!of!the!drug,14!
downregulation! of! deoxycytidine! kinase15! (which! prevents! the! metabolism! of! the!
drug! into! the! active! monophosphate! form),! and! overexpression! of! the! catabolic!
enzymes! that! process! gemcitabine! into! 2’,2’Tdifluorodeoxyuridine! (dFdU),! a! toxic!
metabolite.16! The! application! of! the! ProTide! approach! on! gemcitabine! lead! to! a!
family! of! compounds! which! overcome! all! of! these! resistance! mechanisms:! 1)! by!
entering! the! cell! by! passive! diffusion! into! the! cells! without! the! need! of! hENT!
transporters,! 2)! by! releasing! the!monophosphate! species! independently!of! kinases!
and! 3)! by! showing! resistance! towards! deoxycytidine! deaminase,! and! therefore!






lead! NUCT1031! reached! phase! III! clinical! studies! where! high! intracellular! levels! of!
gemcitabine! triphosphate! were! confirmed.! The! drug! was! well! tolerated! and!
significant!disease!control!was!achieved!in!the!majority!of!patients.18,19!
Another!important!example!of!anticancer!ProTides!is!NUCT3373,!a!ProTide!of!
5Tfluoro!deoxyribouracil! (FUDR),!an!anticancer!drug!derived! from!5TFluorouracil! (5T
FU).20! FUDR! is! the! deoxyribonucleoside! of! 5TFU! and!was! designed! to! facilitate! the!
intracellular!conversion!into!the!active!metabolite!which!is!the!monophosphorylated!
form! 5TfluoroT2’TdeoxyuridineT5’Tmonophosphate.! They! are! largely! used! against!
colon! and! breast! cancer! The!main!mechanism! of! action! of! 5TFU! and! FUDR! is! the!
inhibition! of! thymidylate! synthase! (TS),! and! consequently! the! inhibition! of! DNA!
synthesis,!which!leads!to!apoptosis.21!
TS! catalyses! the! conversion! of! deoxyuridine! monophosphate! (dUMP)! into!
thymidine!monophosphate! (TMP).! This! is! the! only!de# novo! source! of! TMP.! In! the!












change# of# the# conformation# in# the# nucleoside# that# induces# the# ring# opening# of# the# cofactor# 5,10,
methylenetetrahydrofolate#(5,10,CH2,THF)#which#lies#in#an#adjacent#position.#Then#a#cysteine#residue#in#the#active#
site#undergoes#a#Michael#addition#with#the#unsaturated#carbonyl#system#in#dUMP#to#give# intermediate#enolate.#
The# enolate# attacks# the# cation# of# the# cofactor# forming# a# covalent# ternary# complex# (blue# square).# Then# the#
abstraction#of# the#proton#at#position#5#of#dUMP# in# the# complex#promotes#a#β,elimination#of# the# cofactor,# and#
generates#a#methylene#intermediate#of#the#nucleoside.#The#reduction#of#the#methylene#by#transfer#of#a#hydrogen#
atom# from# the# cofactor# and# subsequent# release# of# the# enzyme,# leads# to# thymidine# monophosphate# (TMP).#




responsible! for! the! first! phosphorylation! step,! increased! activity! of! thymidine!
phosphorylase! (that! cleaves! the! nucleobase! from! the! sugar! by! introducing! a!
phosphate!at!position!1’),!and!reduced!transporter!mediated!cellular!uptake.21!The!
ProTide!approach!was!rationally!applied!to!this!drug!and!proved!not!only!to!retain!







in! acidic! and! neutral! pH,! as! well! as! in! plasma;! suggesting! a! mainly! intracellular!
activation.20!NUCT3373,!the!best!ProTide!in!the!family,!is!currently!undergoing!phase!
I!clinical!trials.23!!
Thymectacin! is! a! ProTide! of! brivudine.! Interestingly,! despite! the! anticancer!
effects! of! thymectacin,! brivudine! is! an! approved! oral! treatment! against! severe!
herpes! zoster! infection.! Its! activity! as! antiviral! therapeutic! depends! on! its!





As! mentioned! before,! due! to! the! ability! of! the! ProTides! of! masking! the!
negatively! charged! phosphate! group,! they! can! enter! into! the! cell! through! passive!
diffusion,!in!the!same!way!as!many!other!pronucleotides.!However,!what!makes!the!
ProTide! approach! so!distinct! is! the!mechanism!by!which! the!monophosphorylated!
NA! is! released! (Scheme! 2.2).! Once! the! ProTide! is! inside! the! cell! and! the!masking!
groups! are! cleaved! to! release! the!monophosphorylated!NA,! it! cannot! exit! the! cell!
anymore!because! there!are!no! suitable! channels! for! it! and! the!negatively! charged!




The! activation! of! a! ProTide! is! postulated! to! happen! in! four! steps! (Scheme!













by! spontaneous! hydrolysis! caused! by! the! attack! of! a! water! molecule! at! the!
phosphorus! centre.27,29! Finally,! a! phosphoramidase! type! enzyme,! putatively!
belonging!to!the!HINT!family,!mediates!a!reaction!to!cleave!the!L,amino!acid!moiety!
from!the!molecule,!and!hence!releases!the!monophosphorylated!NA.30!!
The! first! activation! step,!which! is! principally! performed! by! the! intracellular!







step! of! phosphonates28,31! and! phosphorodiamidates.32! In! some! cases! (e.g.!
Sofosbuvir),! the! enzyme! showed! a! preference! for! the! activation! of! one! of! the!




















identifying! moieties! which! have! repeatedly! led! to! better! results! in! the! ProTide!
approach!even!if!the!behaviour!of!each!NA!is!different.34!The!chosen!moieties!in!this!
work! correspond! to! these! most! successful! ones:! LTAlanine! (LTAla)! as! amino! acid,!
naphthyl!(Naph)!and!phenyl!(Ph)!as!aryl!residues!(Ar),!and!neopentyl!(Neop),!benzyl!
(Benz!or!Bz),!ethyl,!hexyl! (Hex),!cyclohexyl! (cHex),! isopropyl! (iPr)!and!octyl!as!ester!
moieties!were!selected.!!
Synthesis9of9amino9acid9esters9
















Compound9 (R)9 Amino9Acid9 Yield9
2.19 Neopentyl! L,Alanine! 77!%!
2.29 Hexyl! L,Alanine! 76!%!
2.39 Cyclohexyl! L,Alanine! 84!%!
2.49 Isopropyl! L,Alanine! 95!%!
2.59 Octyl! L,Alanine! 50!%!
!
Synthesis9of9Aryl9Phosphorodichloridate9
! Phenyl! phosphorodichloridate! is! commercially! available,! so! the! designed!
ProTides!only!required!the!synthesis!of!1Tnaphthyl!phosphorodichloridate!2.6.!It!was!




















chlorinated! salt! in! the! presence! of! triethylamine.! This! reaction! required! 2!
equivalents!of!the!base.!The!first!equivalent!replaces!the!salt.!Then!the!lone!pair!of!
electrons! of! the! amino! group! of! the! aaTester! attacks! the! phosphate! at! the!
phosphorus! atom! and! displaces! one! chlorine! atom.! The! second! equivalent! of!
triethylamine!will! accept! the! additional! proton! of! the! amino! group.! This! is! a! nonT
stereoselective! reaction! and! two! diastereoisomers! (LAla,Rp)! and! (LAla,SP)! will! be!




The! removal! of! the! tosylated! salt! from! the! crude! was! achieved! either! by!
filtration!of!the!crude!with!diethyl!ether!(in!which!the!product!is!soluble!but!the!salt!
is! not)! or! by! a! rapid! chromatographic! column! to! retain! the! salt! in! the! silica.! The!
faster!this!process!was!performed,!the!better!yields!were!observed.!!
Table92.2:9Summary!of!the!synthesised!phosphorochloridates!showing!the!yields!and!31P!NMR!shifts!in!CDCl39
Entry9 R9 Aryl9(Ar)9 Yield9 31P9NMR99
2.79 Neop! Naphthyl! 63!%! 8.28,!8.02!ppm!
2.89 Benz! Naphthyl! 63!%! 8.33,!8.05!ppm!
2.99 Ethyl! Naphthyl! 53!%! 8.33,!8.06!ppm!
2.109 Hexyl! Naphthyl! 90!%! 8.25,!7.98!ppm!













groups! of! the! nucleoside! analogue.! On! the! other! hand,! it! easily! attacks! the!
phosphorochloridate,! forming! a! labile! intermediate! that! is! being! attacked! by! the!
most! acidic! hydroxyl! of! the! nucleoside,!which! is!most! often! the! 5’! hydroxyl! group!
(typically!the!only!primary!alcohol),!to!form!the!ProTide!(Scheme!2.7).!This!method!is!






The!Grignard! reagent! tertTbutyl!magnesium!chloride! (tBuMgBr)! is!used!as!a!
strong! base.! It! removes! the! proton! of! one! hydroxyl! group! in! the! NA,! usually! at!
position! 5’! because! it! is! the! least! hindered! and!most! acidic.! The! generated! anion!


































Entry9 R! Aryl9(Ar)! Yield! 31P9NMR9!
2.129 Neop! Phenyl! 77%! 7.64,!7.98!ppm!
2.139 Benz! Phenyl! 88!%! 7.89,!7.57!ppm!
2.149 Ethyl! Phenyl! 82!%! 8.06,!8.33!ppm!
2.159 Hexyl! Phenyl! 77!%! 8.03,!7.71!ppm!
2.169 cHex! Phenyl! 77!%! 8.12,!7.75!ppm!
2.179 iPr! Phenyl! 53!%! 8.06,!7.69!ppm!






NMI!and! can!easily!deprotonate!other!hydroxyl! groups! in! the!molecule.! It! is!often!
the!preferred!method!for!NA!that!have!a!free!hydroxyl!group!only!at!the!5’!position!

































synthesis! new! families! of! ProTides! of! novel! and! known! anticancer! NA! in! order! to!
improve!their!potential!therapeutic!application!
The! targeted! NAs! were:! 2Tchlorocordycepin,! 3’Tethynyl! nucleosides! (with!
focus! on! 3’Tethynyluridine,! 3’Tethynylcytidine! and! 3’TethynylT5Tmethyluridine),! and!
the!new!nucleoside!3,N4Tethenogemcitabine.!
The!new!compounds,! along!with! their!parent!nucleosides,!were! then! to!be!
tested! for! their!activity! in!an! in#vitro! cellTbased!assay.!Moreover,!enzymatic!assays!




As! these! compounds! were! expected! to! emit! fluorescence,! experiments! to!
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by! the! absence! of! hydroxyl! group! at! the! 3’! position.! It! was! first! isolated! as! a!
biometabolite!from!Cordyceps#militaris!in!the!nineteen!fifties,1!and!it!is!also!present!
in! Cordyceps# sinensis.2# Cordyceps! is! a! caterpillar! parasite! fungus! with! medicinal!
properties! widely! used! in! traditional! Chinese! medicine.! There! it! has! broad!
applications!because!of!its!numerous!attributed!pharmacological!properties.3!9
This!caterpillar!fungus!grows!in!the!Himalayan!lands,!on!the!Tibetan!Plateau,!
above! 3800!m! above! sea! level.! Demand! of! this! mushroom! due! to! its! interesting!
properties!has! increased.!However! its!availability! is! limited!because!of! its! confined!
geographic! location.! In! addition,! the! Chinese! government! protects! Cordyceps!#
sinensis!by!listing!it!as!the!key!wild!species!under!second!grade!state!protection!and!
promulgating! laws! and! regulations! to! protect! the! fungus’! sustainable! use,!
development! and! collection.4! Therefore,! acquisition! of! the! desired!metabolites! of!
Cordyceps# sp.! is! subject! to! artificial! culture! or! chemical! synthesis.! Nowadays,! an!
efficient!method!in!organic!synthesis!allows!access!to!cordycepin!from!adenosine!in!
a!twoTstep!synthesis.59
The! described! properties! of! cordycepin! cover! such! diverse! claims! like!
antifungal6!and!trypanocidal!activity,7,8!antiTinflammatory!properties,9!and!inhibition!
of! platelet! aggregation.10! However,! the! most! reported! ones! are! the! anticancer!
activities!of!this!compound:!There!are!studies!showing!antiTtumour!effects!on!mouse!


























as! the! ability! of! cordycepin! triphosphate! to! inhibit! the! action!of! RNA!polymerases!
(Poly(A)! synthesis! is! preferentially! affected).21! Later,! it! was! discovered! that! the!
synthesis!of!the!DNA!primer!was!also!affected,22!and!more!recently!an!inhibition!of!
the!action!of!terminal!deoxynucleotidyl!transferases!(TdT)!was!also!described.15!
However! the! exact!molecular!modes! of! action!of! this! drug! remain! unclear.!
Since! cordycepin! triphosphate! is! an! adenosine! triphosphate! (ATP)! analogue,! the!
nucleotide!can!interfere!with!numerous!cellular!processes!that!require!ATP!binding!
or! hydrolysis.20! In! the! first! attempt! to! elucidate! the! mechanism! of! action! of!
cordycepin!in#vitro!assays!were!performed!to!check!if!cordycepin!could!act!as!chain!
terminator!due!to!the!lack!of!the!hydroxyl!group!at!position!3’.!Müller!et#al.!(1977)!
proved!that!cordycepin!triphosphate!competes!with!ATP!for! the! incorporation! into!
the!RNA!chain,!especially!in!enzyme!systems!containing!nuclear!poly!(A)!polymerase,!
which! then! leads! to! termination! of! the! chain.18! Later,! Holbein! et# al.! (2009)!
performed! more! exhaustive! studies! on! the! molecular! basis! of! the! activity! of!
cordycepin.20!Those!studies!agreed!that!the!toxic!species!is!cordycepin!triphosphate,!
and!that!the!activity!is!counteracted!by!the!presence!of!ATP.!They!also!proved!that!
cordycepin! triphosphate! can!act! as! a! chain! terminator,! but! found! that! the!nuclear!
concentration! of! cordycepin! triphosphate! is! too! low! to! cause! significant! chain!
termination.! However,! it! was! sufficiently! high! to! reduce! efficiency! of! 3’! end!
formation.!Therefore!they!described!that!the!ability!of!interfering!in!the!formation!of!







The! efficacy! of! cordycepin! is! compromised! by! the! rapid! metabolic!
degradation!by!adenosine!deaminase!(ADA),!which!is!ubiquitous!in!almost!all!human!
tissues.23!!
ADA! is!a!major!enzyme!of!purine!metabolism! responsible! for! conversion!of!
adenosine! and! 2’Tdeoxyadenosine! into! their! corresponding! inosine! derivatives.! It!
was!shown!that!ADA!interacts!with!cordycepin!3.1!with!similar!kinetic!parameters!as!
adenosine,24!and!this! interaction!irreversibly! leads!to!3’Tdeoxyinosine!3.3! that! lacks!
cytotoxic!activity.15!The!catalytic!mechanism!proposed!for!this!process!is!the!same!as!





There! are! two! approaches! to! endow! cordycepin! with! resistance! towards!
ADA.! The! first! is! the! coTadministration!with! an! ADA! inhibitor,! and! the! second! the!
modification!of!the!molecule!with!groups!that!may!provide!resistance!towards!ADA!
without!compromising!its!activity!
As! an! example! for! the! first! approach,! the! combination! of! cordycepin! with!
(8R)T2’Tdeoxycoformycin! 3.4! (henceforth! referred! to! as! deoxycoformycin)! was!
investigated.! Deoxycoformicin! 3.4! is! a! potent! ADA! inhibitor! whose! activity! is!




















































This! combination! enhanced! the! anticancer! and! trypanocidal! activity! of!
cordycepin!3.1!in!cells!and!in!mice.8,26,27!However,!inhibiting!an!enzyme!such!as!ADA,!
which! is! ubiquitous! in! the! body,! may! lead! to! unspecific! toxicity! and! indeed,!
deoxycoformicin! 3.4! is! used! as! an! anticancer! agent! in! hairy! leukaemia28! and! also!
exhibits! teratogenic! effects.29! Because! of! this! cytotoxicity,! the! dose! needs! to! be!
monitored! carefully.! When! the! coTadministration! of! cordycepin! 3.1! and!
deoxycoformicin! 3.4! was! studied! in! Beagle! dogs,! it! led! to! severe! gastrointestinal!
toxicity! and! bone! marrow! toxicity,! establishing! the! maximum! tolerated! dose! of!
cordycepin! in! combination! with! deoxycoformicin! in! 8! mg/kg/day.30! Those! effects!
may! limit! the! coTadministration! in! human.! Two! Clinical! trials! administering!
cordycepin! in! combination! with! deoxycoformycin! for! treatment! in! patients! with!
refractory!TdTTPositive!Leukaemia!and!with!refractory!acute!lymphocytic!or!chronic!
myelogenous! leukaemia!were! carried! out! however,! to! date,! no! study! results! have!
been!posted.16!
The! second! strategy! to! provide! cordycepin! with! resistance! to! ADA!
deamination!is!to!modify!the!molecule!so!that!it!is!no!longer!an!ADA!substrate.!Such!
modifications! were! explored! in! the! course! of! this! thesis,! with! focused! interest! in!
modifications!at!position!5’!and!position!2.!
!Some! studies! have! shown! the!
importance! of! the! hydroxyl! group! at!
position!5’! for! the!activity!of!ADA.! Figure!
3.1! shows! the! schematic! pocket! site! of!
ADA!and!the! interactions!with!adenosine,!
the!natural!substrate.23!!
When! position! 5’! of! cordycepin!
was! acetylated,! ADA! totally! lost! its!
activity.! It! is! postulated! that! the! lack! of!

















to! both! ADA! deamination! resistance,! and! inhibitors! of! ADA.23! For! example,! 2T
Chloroadenosine24!and!Cladribine! (2TchloroT2'Tdeoxyadenosine,!a!potent!anticancer!
nucleoside! analogue)33! were! shown! not! be! substrates! of! ADA.! The! postulated!
mechanism!of!resistance!for!CT2Thalogenated!adenosine!nucleosides!states!that!the!








against! human! T! and! B! lymphocytes! and! mouse! fibroblasts! discouraged! further!
research.35!It!was!also!tested!as!an!apoptotic!agent!in!peripheral!blood!mononuclear!
cells,! but! only! poor! effects! were! observed! compared! to! cladribine.36! Finally,! 2T
chlorocordycepin!was! tested! as! an! antibacterial! agent,! but! the! compound! did! not!
show! activity.37! Recently,! the! compound! was! further! evaluated! as! a! trypanocidal!


























intends! to! improve! the!activity!of! cordycepin!by!providing! resistance! towards!ADA!
metabolic! degradation! and! by! supplying! high! intracellular! concentrations! of! the!









Several! published! procedures! for! the! synthesis! of! 2Tchlorocordycepin! are!
available.! They!were! scrutinized! for! applicability! and! feasibility! for! the! purpose! of!
this!work.!
!Synthesis! of! 2Tchlorocordycepin! was! first! reported! by! Rosowsky! et# al.! in!
1989.35# Starting! from! commercially! available! 2Tchloroadenosine,! a! three! step!
synthesis!lead!to!a!mixture!containing!2Tchlorocordycepin,!with!an!overall!yield!of!15!
%! after! purification! (Scheme! 3.5).! The! synthesis! involves! the! protection! of! the!
hydroxyl! group! at! position! 5’! of! 2Tchloroadenosine! with! a! 4,4’Tdimethoxytrityl!
(DMTr)! group,! followed! by! the! condensation! with! 1,1’Tthiocarbonyldiimidazole! in!
acetonitrile,!giving!the!2’,3’TOTthiocarbonyl!derivate.!Then,!treatment!with!nTBu3SnH!
in!toluene!in!the!presence!of!α,α’Tazobisisobutyronitrile!(AIBN)!results!in!a!mixture!of!




desired!nucleoside! from!2Tchloroadenine! (Scheme!3.6).! In! this! synthesis! the!amino!
group! of! 2Tchloroadenine! is! protected!with! heptanoic! anhydride! to! be! condensed!
with! 1TchloroT2,5TdiTOTbenzoylT3TdeoxyTDTribose! using! potassium!















































































































































! Because! of! the! inadequacy! of! these! reported! procedures! a! novel! route! to!
obtain!2Tchlorocordycepin!was!designed.!This!new!pathway!based!on!the!cordycepin!
synthesis! by! Robins! et# al.! 5! aimed! for! a! twoTstep! synthesis! starting! at! 2T
chloroadenosine!3.5,!which!is!commercially!available!(Scheme!3.9).!Even!though!no!
evidence!for!previous!attempts!of!this!synthetic!pathway!was!found!in!the!literature,!
this! method! was! chosen! because! it! is! short,! inexpensive! and! delivered! only! one!
product.!!
!
The! first! step! involved! the! conversion! of! 2Tchloroadenosine! 3.5! into! 2T
chloroadenosineT2’,3’Triboepoxide! 3.6.! 2TChloroadenosine! 3.5! was! treated! with!αT
acetoxyisobutyryl! bromide! (αAIBBr)! in! dry! acetonitrile! with! 1! equivalent! of! water!





































































































that! the! stereoselectivity! was! due! to! sterical! impediments.! The! reaction! with! 2T
chloroadenosine!3.5!was!expected!to!act!in!the!same!way,!so!only!two!intermediates!
would! be! formed! 3.7a! and! 3.7b! and! would! acquire! alpha! configuration! for! the!
acetoxy!moiety! and! beta! for! the! bromine,! as! it! is! shown! in! the! Scheme! 3.10.! The!
intermediates! were! not! isolated! and! the! next! step! was! done! without! further!
purification.!!
!
The! reaction!was! then! treated!with!amberlite! IRN!78! (OH)T.! It! is!postulated!
that! the! OHT! groups! in! this! resin! would! attack! intermediate! 3.7! on! the! activated!
carbon! bearing! the! bromine! substituent! (C2’! or! C3’).! The! bromine! atom! is! a! good!
leaving!group!and!it!can!be!cleaved.!Then,!the!lone!pair!of!electrons!of!the!hydroxyl!
group!attacks! the! carbon!bond! to! the!acetoxy!moiety,! to! form!2TchloroadenosineT








key!differences! are!noted:! two!doublet! signals! corresponding! to! the!proton! in! the!





























































change! of! the! conformation! when! the! sugar! is! bearing! an! epoxide! instead! of! an!
alcohol:!HT1’!and!HT2’!adopt!a!torsion!angle!very!close!to!90!degrees.43!According!to!
the! Karplus! equation! in! these! conditions! the! magnitude! of! J! coupling! constants!










using! lithium! triethylborohydride.! In! 1980! Brown! et# al.! described! the! regio! and!
stereoselectivity! of! the! process! that! takes! place.44! Under! these! conditions,! the!
reaction!yields!exclusively!the!Markovnikov!alcohol:! the!reducing!agent!attacks!the!
Compound9 Attempt9 3.59 Time9 Yield9
3.69 A! 0.2!g9 (1)!2!h,!(2)!4!h! 33!%9
3.69 B! 1.0!g9 (1)!2!h,!(2)!20!h! 54!%9
3.69 C! 3.8!g9 (1)!2!h,!(2)!23!h! 41!%9
3.69 D! 5.0!g9 (1)!2!h,!(2)!3!h! 60!%9








less! hindered! position! of! the! epoxide! 3.6,! position! 3’,! releasing! the! alcohol! at!
position! 2’,! and! therefore! giving! one!molecule! of! 2Tchlorocordycepin!3.29 (Scheme!
3.12).!
9
! In! the! literature! this! reaction! is! described! to! yield! about! 90! %! for! nonT
chlorinated!analogues.5!Here,!when!the!reaction!was!performed!with!the!chlorinated!
species,! the! best! achieved! yield! for! 2Tchlorocordycepin! 3.2! was! 69! %,! observing!
nonetheless! that! the! yield! improved! by! increasing! the! quantity! of!3.6.! In! the! first!
batch!of!2Tchlorocordycepin!3.2B,!a!salt!from!the!lithium!hydride!was!observed!after!
the! work! up! of! the! product.! Low! reactivity! was! noticed! when! 3.2B! was! used! to!





Purification! by! recrystallization! in! methanol! achieved! the! pure! compound! (3.2E).!
Table#3.2!summarises!the!different!conditions!tested!to!achieve!2Tchlorocordycepin.!
Table93.2:9Summary!of!the!quantity!of!starting!material!(SM)!and!time!used!to!achieve!2Tchlorocordycepin.9
Compound9 Attempt9 Conditions9 Purification9 Yield9
3.29 A! 3.6!=!64!mg;!4!eq!LiEt3BH!24!h9 T! No!reaction9
3.29 B! 3.6!=!800!mg;!10!eq!LiEt3BH!20!h9 T! 22!%9
3.29 C! 3.6!=!2180!mg;!4!eq!LiEt3BH!3!h9 Filtration!on!silica!gel! 55!%9
3.29 D! 3.6!=!1655!mg;!4!eq!LiEt3BH!20!h9 Filtration!on!silica!gel! 69!%9
3.29 E! 3.6!=!6112!mg;!4!eq!LiEt3BH!20!h! Recrystallisation! 62!%!
! !
The!identity!of!2Tchlorocordycepin!was!established!by!mass!spectroscopy!and!












































3’! is# observed." As" the" conformation" of" the" sugar" changes$ again,$ a$ narrow$doublet$
corresponding+to+the+proton+at+position+1’+is+perceived,+instead+of+the+singlet+in+the+
epoxide,(or(the(triplet(that(according(to(the(literature(shows%for%the%isomer%2’TdeoxyT
2Tchloroadenosine! (Cladribine).45!Only$one# singlet# at# 8.41% ppm% (in% CD3OD)$ for$ the$
proton&at&position&8&in&the&base&means&that&position&2&was!substituted.)!
!














! Three! strategies! were! used! to! synthesise! 2Tchlorocordycepin! ProTides:! 1)!
using! NMI! reagent,! 2)! using! Grignard! reagent! and! 3)! using! Grignard! reagent! with!
selectively! protected! 2Tchlorocordycepin.! These! strategies! are! described! in! the!
following!sections.9
Using9NMI9reagent9
The!first!approach!was!to!use!NMI!reagent!since! it! is! the!preferred!method!
for!NA!with!several!hydroxyl!groups!(Scheme!3.13).!The!first!attempts!for!ProTiding!

















The! following! reactions! were! performed! with! repurified! batches! of! 3.2! to!





Comp.9 3.29 Yield9 31P9NMR9Shift99 EI/MS9[M+H+]9
3.99A9 100!mg9 T9 4.30,!4.15!ppm9 633.2!
3.99B9 150!mg! 1!%! 4.30,!4.15!ppm!! 633.2!
3.109 100!mg9 3!%9 4.39,!4.12!ppm!9 653.2!
3.119 90!mg9 3!%9 4.31,!4.21!ppm!9 591.1!






































9 R9 Ar93.169 Benz! Naph!
3.179 Benz! Ph!
Under! these! conditions,! the! reactions! went! to! completion! in! a! shorter!




13C! NMR! and! HSQC! analysis! proved! that! the! 2’! regio! isomer! was! formed!
instead!of!the!desired!5’TProTide.!Figure!3.4!shows!the!13C!NMR!of!compound!3.16.!A!
doublet! signal! (one! doublet! for! each! diastereoisomer)! for! CT2’! showed! the! PTOTC!
coupling!and!for!CT1’!the!longTrange!PTOTCTC!coupling!with!the!phosphorus!atom!of!
Comp.9 3.29 Yield9 31P9NMR9Shift9
3.99C9 350!mg9 34!%9 4.35,!4.20!ppm9
3.139 350!mg! 25!%!! 3.93,!3.72!ppm!
3.149 288!mg! 15!%! 3.94,!3.74!ppm!
3.159 339!mg! 28!%! 3.98,!3.76!ppm!
Entry9 3.29 Yield9 Observations9 EI/MS9[M+H+]9 31P9NMR9
3.169 200!mg9 7!%9 2’!ProTide!achieved9 653.29 3.93,!3.72!ppm!
































! Since! those!species!would!not!deliver! the!nucleoside!5’Tmonophospate! into!





on! selectively! protected! 2Tchlorocordycepin! (Scheme! 3.15).! It! first! required! the!
protection! of! both! hydroxyl! groups! in! 2Tchlorocordycepin! 3.2! with!
tertbutyldimethylsilyl! (TBDMS)! groups! delivering! the! bisTsilylated! compound! 3.18,!
followed! by! the! selective! deprotection! of! the! hydroxyl! at! position! 5’! (compound!
3.19).! Next,! a! coupling! reaction! using! tBuMgCl! were! to! deliver! the! protected! 5’!
ProTide.! A! final! deprotection! step! would! then! give! the! desired! final! product.! The!
TBDMS!group!was!chosen!because!it!is!easily!introduced!with!different!reagents,!it!is!
stable! to! a! variety! of! organic! reactions! especially! towards! bases,! and! it! can! be!







































































The! attempts! to! achieve! compound! 3.18! are! summarised! in! Scheme! 3.16.!
The!protection!of!both!hydroxyl!groups!with!TBDMSCl!was!first!performed!following!
a!protocol!by!Halligan!et#al.!46!where!pyridine!was!used!as!a!base!and!solvent!during!
the! reaction! (a).! Under! these! conditions! the! bisTsilylated! compound! 3.18! was!
achieved!in!10T16%!yield.!The!main!product!in!this!reaction!was!the!5’Tmonosilylated!
derivative! 3.24,! which! was! achieved! in! a! 34! %! yield.! Silylation! at! position! 5’! was!
proved! due! to! the! 1H! NMR! spectrum! in! CDCl3! showing! the! free! proton! of! the!
hydroxyl! group! at! position! 2’.! The! preferential! formation! of! the! 5’! protected!
derivative! instead! of! the! 2’! or! bisTsilylated! species! can! be! explained! by! the! low!
reactivity!of!the!secondary!alcohol!at!position!2’!as!a!nucleophile.!In!the!reaction!5’T
hydroxyl! group!would! react! with! the! silicon! atom,! and! pyridine!would! accept! the!
proton!formed!in!the!reaction.!
Further! investigations!were!done! to! set!optimal! conditions.! It!was! found! in!
the! literature!that!a!solution!of! imidazole! in!N,NTdimethylformamide! (DMF)!should!
deliver!the!best!yields!for!adenosine!deoxynucleosides!in!this!reaction.47,48!DMF,!as!
an!aprotic!solvent,! facilitates! reactions! that! follow!polar!mechanisms,!such!as!SN2.!



















3.18! resulting! in! a! successful! reaction! yielding! 72! –! 74! %! of! the! 2’! monosilylated!
species!3.199(Scheme!3.16,!(c)).!9








! Total! desilylation! of! the! achieved! ProTides! was! then! performed! using!
stronger! conditions! than! those! to! selectively! deprotect! 2Tchlorocordycepin.! The!
silylated!ProTides!were!dissolved!in!1mL!of!THF!and!a!solution!of!TFATH2O!(5.5:4.5)!
was! added! at! 0! ˚C! and!was! slowly! allowed! to! reach! RT.! After! 24! h,! the! reactions!
showed! no! further! progression! even! if! TLC! showed! there! was! still! some! starting!
material! left.!The!yields!of!these!reactions!were!lower!than!expected!at!52!–!66!%,!


































































considered! to! be! less! successful! than! the! second! strategy! using! NMI,! because! it!
afforded!lower!yields!and!is!a!longer!process.!
Table93.7:!Summary!of!the!deprotection!of!the!silylated!ProTides.!Overall!yield!through!all!the!process.9
Compound9 Starting9Material9 Yield9 Overall9Yield99
3.109 3.20!=!90!mg9 52!%9 18!%9
3.239 3.21!=!93!mg9 66!%9 13!%9

















The! cytotoxicity! of! the! compounds!was! tested! against! a! diverse! sample! of!
blood! cancer! cells!measuring! the! cell! viability! of! leukemic! (the!main! indication! of!















































highest! concentration!was! 198! μM! and! the! lowest! concentration!was! 0.0199! μM.!
The! selected! cell! lines!were! incubated!with! the! different! doses! of! the! compounds!
over!72!hours,!and!then!the!cell!viability!was!measured.!The!resulting!doseTresponse!
curve!was!analysed!using!XLTfit! software.!The!half!maximal!effective!concentration!
(EC50)! and!Top! Inhibition!percentage! (percentage!of!nonTviable! cells! at! the!highest!












CCRFTCEM! MOLTT4! K562! HEL92.1.7! KGT1! MV4T11! HLT60!
EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%!
2"ClCordy9! >198! 38! >198! 57! >198! 39! 82! 56.0! >198! T0.2! 65! 98! 104! 62!
3.99 15! 99! 9! 100! 18! 99! 6! 104! 25! 100! 5! 100! 13! 100!
3.109 9! 100! 10! 100! 24! 101! 8! 100! 30! 99! 6! 101! 14! 102!
3.139 67! 98! 45! 99! 81! 82! 29! 96! 64! 90! 1! 100! 66! 95!
3.149 80! 94! 36! 99! >198! 7! 89! 82! T! T! T! T! 190! 53!
3.159 86! 83! 52! 99! >198! 22! 107! 58! T! T! T! T! 100! 70!
3.239 43! 98! 58! 124! 57! 87! 74! 92! 75! 71! 9! 100! 95! 68!
4.199 72! 87! 42! 99! >198! 50! 59! 74! T! T! T! T! 116! 70!






ThpT1! ZT138! RL! Jurkat! HsT445! RPMIT8226! NCITH929!
EC50! TI!%! EC50! TI!%! EC50! TI%! EC50! TI%! EC50! TI%! EC50! TI%! EC50! TI%!
2"ClCordy9! >198! 8! >198! 42! >198! 39! >198! 3! >198! <50! >198! 36! 103! 68!
3.999 31! 99! 8! 100! 12! 100! 26! 101! 27! 102! 33! 100! 19! 99!
3.1099 63! 97! 60! 90! 11! 100! T! T! 40! 106! 29! 100! 7! 102!
3.1399 84! 90! 39! 97! 49! 85! 100! 67! >198! <50! 83! 99! 74! 77!
3.149 T! T! 189! 55! 176! 54! T! T! >198! 28! 79! 97! T! T!
3.159 T! T! 101! 67! >198! 53! T! T! >198! 27! >198! 50! T! T!
3.2399 97! 72! 62! 78! 40! 85! >198! 36! 198! <50! 176! 51! 60! 77!
4.199 T! T! 28! 103! 94! 79! T! T! 87! 82! 6! 95! T! T!
Paclitaxel! T! T! 0.004! 99! 0.01! 79! T! T! 0.005! 89! 0.003! 96! T! T!
'
2TChlorocordycepin!3.2! was! inactive! in!most! of! the! blood! cancer! cell! lines,!
where! the! EC50! value!was! higher! than! the! highest! concentration! tested! (198!µM).!















was! comparable! to! 3.10! and! 3.9! in! the! cell! line! ZT138,! while! it! was! slightly!more!
active!and!in!the!cell!line!RPMIT8226.!Compounds!bearing!a!long!aliphatic!chain!3.14!


















Pancreas! Pancreas! Colon! Colon! Liver! Breast! H&N!
MiaTPaTCaT2! BxPCT3TLuc! HT29! SW620! HepG2! MCFT7! Cal!27!
EC50! TI%! EC50! TI%! EC50! TI%! EC50! TI%! EC50! TI%! EC50! TI%! EC50! TI%!
2"ClCordy9! >198! 4! >198! T0.5! >198! 3! >198! 4! >198! 10.2! >198! 2.4! >198! T2!
3.999 35! 99! 79! 98! 69! 98! 40! 101! 66! 98! 33! 101! 54! 99!
3.1099 31! 98! 71! 82! 72! 88! 37! 92! 56! 85! 31! 101! T! T!
3.1399 140! 56! >198! 9! >198! 33! 155! 57! >198! 42! 174! 58! 114! 57!
3.149 95! 75!
!
T! >198! 52! T! T! >198! 39! 127! 67! 177! 53!
3.159 103! 84! T! T! 126! 60! T! T! 114! 66! 93! 81! 155! 57!
3.2399 >198! 50! >198! 13! >198! 15! >198! 44! >198! 55! >198! 42! >198! 25!
4.199 16! 93! T! T! >198! 47! T! T! 168! 55! 91! 58! 146! 60!








Top! inhibition! ranged! T1.8! %! to! 10.2! %,! and! the! estimated! EC50! value! always!
exceeded!the!highest!concentration!198!µM.!
!As! in! the! case! of! haematological! malignancies,! all! ProTides! increased! the!
activity!of! the!parent!nucleoside! in! the! solid! tumour! cells.! The!best! compounds! in!
the! series,! characterised! by! the! lowest! EC50,! were! again! 3.99 and! 3.10! whose! EC50!
ranged! between! 31! and! 79! µM,! with! high! values! (~100! %)! of! top! inhibition.!
Compound!3.9!improved!the!activity!of!the!parent!nucleoside!6Tfold!for!MCFT7!cells!












These! data! suggest! a! preference! in! the! activity! of! the! compounds! for!
haematological!malignancies.!

















carboxypeptidase!Y! enzymatic! assay! (Table#3.12).! This! assay! aims! to! analyse! if! the!
different! performance! of! the! ProTides! is! related! to! any! difference! in! the! first!
activation! step! of! the! prodrug.! This! is! achieved! by! determining! whether! the! 2T
chlorocordycepin! ProTides! can!be!processed!by! the! enzyme! that!was! identified! as!








As! described! in! the! second! chapter,! a! carboxypeptidase! enzyme! (mainly!
Cathepsin!A)!initiates!the!intracellular!release!process!of!the!nucleotide!analogue.!As!
human!Cathepsin!A!is!not!commercially!available,!carboxypeptidase!Y!was!chosen!as!
a! model! enzyme.! Both! enzymes! belong! to! the! same! family! of! CTtype!
carboxypeptidases,! and! exhibit! a! high! degree! of! structural! homology! around! the!
catalytic!site.50!
The! experiment! measures! the! 31P! NMR! shift! of! selected! compounds! in!




Two! intermediate! compounds! are! often! observed! in! this! experiment:! the!







The! aminoacyl! phosphoramidate! would! then! require! another! enzyme,! a!
phosphoramidase,!to!finally!release!the!monophosphorylated!NA.!
This! experiment!was! first!performed!with!7!mg!of!3.9.! In! the!blank! sample!
containing! the!mixture!of!diastereoisomers,! two!signals!are!observed!at!3.85,!3.62!
ppm! (A).! After! addition! of! the! enzyme! at! minute! 7,! the! formation! of! two! small!
signals! downfield! (B,! C)! was! noted,! while! one! of! the! diastereoisomers! slowly!
disappeared.!Signal!B!corresponds!to!the!hydrolysed!intermediate!(4.77!ppm),!which!
quickly! converted! into! the! aminoacyl! intermediate! C! (6.99! ppm)! as! seen! in! Figure!





experiment! was! performed! with! lower! resolution! and! thus! only! shows! the! total!
conversion! of! the! ProTide! (3.85,! 3.60! ppm)! into! the! aminoacyl! phosphoramidate!











3.14.! Here,! the!metabolism! of! the! two! diastereoisomers! of! the! ProTide# (signal! A,!
3.84,!3.66!ppm)!was!observed!without!any!apparent!sterical!preference,! leading!to!









In! the! compounds!3.9! and!3.13! bearing! a! neopentyl!moiety,! a! preferential!
metabolism!for!one!of!the!diastereoisomers!was!observed,!whereas!the!compound!
3.14!bearing!the!hexyl!moiety!did!not!show!any!discrimination!for!either!the!Rp!or!Sp!
diastereoisomer.! That! may! be! due! to! the! flexibility! of! the! hexyl! substituent! in!
comparison! to! the! neopentyl.! The! experiments! showed! that! all! three! compounds!
were! processed! by! the! enzyme,! except! for! one! diastereoisomer! of! 3.9,! which!
surprisingly!is!also!the!compound!that!performed!the!best!in!the!cell!viability!assay.!
This!suggests!two!possibilities:!The!first!one!being!that!compound!3.9!would!follow!
the! pattern! of! compound! 3.13! and! that! the! more! stable! diastereoisomer! would!
eventually! be! converted! by! the! enzyme! if! the! experiment!was! prolonged! or!more!
enzyme!would!be!added.!The!second!possibility!is!that!one!of!the!diastereoisomers!
does!not!get!activated!at!all!by!carboxypeptidase!Y.!Then!either!other!enzymes!in!the!










Sofosbuvir.! This! anti! HVC! ProTide! contains! only! one! diastereoiromer! with! an! Sp!
configuration!of!the!phosphorus!centre.!During!the!development!of!the!drug,!it!was!
noted!that!the!Sp!diastereoisomer!was!more!than!10Tfold!more!active!than!the!Rp!
analogue.51! Studies! to! elucidate! the! mechanism! of! activation! discovered! that!
cathepsin!A!processed!the!Sp!diastereoisomer!18Tfold!more!efficiently!than!the!RpT
diastereoisomer.52!However,! in!our! laboratory! the! synthesised!ProTide!compounds!
usually! exhibited! complete! hydrolysis! independently! of! their! stereochemical!
configuration,!as!exemplified!by!NUCT3373,53!NUCT1031.32!
Adenosine9deaminase9assay9
! The! resistance! of! 2Tchlorocordycepin! and! 3.9! (one! of! the! most! active!
ProTides! in! the! cell! viability! assay)! against! ADA! metabolism! was! tested! using!
cordycepin! (synthesized! following! the!method!by!Rosowsky!et#al.35)!as!a! reference!
compound.!
! In!the!literature!it!is!well!established!that!cordycepin!undergoes!degradation!







The! first! experiment! aimed! to! validate! the! assay! and! to! be! used! as! a!
reference!for!the!subsequent!experiments.!For!this,!cordycepin!(3.1)!was!incubated!
with!ADA!to!create!a!reference!experiment.!The!results!in!Figure!3.8!show!that!the!
maximum!absorbance! in! the!UV! spectrum! shifts! from!259.0!nm! to!249.0!nm.! This!
shift! of! 10! nm! when! the! compound! was! exposed! to! the! enzyme! showed! the!
formation!of!a!new!species.!This!is!in!accordance!with!the!literature24,38!where!it!was!
established!that!the!newly!forming!species!is!the!corresponding!inosine!3.3.!The!shift!









In! the! second! experiment! 2Tchlorocordycepin! 3.2! was! incubated! using! the!
same! conditions! (Figure! 3.9).! The! maximum! wavelength! for! the! compound! was!
265.0!nm.!No!spectral!change!observed!in!UV!spectrophotometer!records!after!24!h!
indicating! a! stability! of! the! substrate! to! the! ADA! metabolism.! This! result! was!
expected! as! other! 2Thalogenated! purines! such! as! Cladribine! (2TchloroT2’T


















































In! the! third! experiment! ProTide! 3.9! was! analysed! in! the! same! conditions!
(Figure!3.10).!The!ProTide!showed!a!maximum!wavelength!of!265.9!nm,!almost!the!







of! cordycepin,!which! is! deamination,! it!was! still! inactive! in!most!of! the! tested! cell!
lines.! This! suggested! that! indeed! the! ProTide! approach!was! necessary! not! only! to!
























These! experiments! were! performed! in! collaboration! with! Doctor! Salvatore!
Ferla.!!
Molecular!modelling! studies!were! performed! to! gain! understanding! on! the!
ester!hydrolysis!of!the!2Tchlorocordycepin!ProTides!in!the!first!activation!step,!and!to!




between! the! diastereoisomers! of! the! ProTide! 3.9! were! observed.! To! better!
understand! the! enzymatic! results,! molecular! modelling! studies! using! the! crystal!
structure!of!carboxypeptidase!Y!available!in!the!protein!data!bank!(PDB!1YSC)54!were!
performed.!According! to! Jung!et#al.! (1999)! the!ester!hydrolysis!process,! requires!a!
suitable! position!of! the! carbonyl!moiety! in! the! enzyme!pocket! for! the!nucleophile!






































































carbonyl! group! in! proximity! of! the! Ser146,! in! an! orientation! that! could! allow! the!
nucleophile!attack!(Figure!3.13)!
!
Docking! results! taken! along! with! the! enzymatic! experiments! would! also!
suggest!a!better!interaction!of!one!of!the!diastereoisomers!with!carboxypeptidase!Y.!
The! S!diastereoisomer! seems!a!potential! good! substrate! for! this! enzyme,!whereas!
the! R! diastereoisomer! does! not! show! a! favourable! docking! pose! for! the! proper!
interaction! with! the! catalytic! site! of! the! enzyme.! These! results! however,! are! not!
Figure' 3.12' Left:# Ser146,# Gly52# and# Gly52# residues# (yellow)# in# the# site# of# action# of# Carboxypeptidase# Y#










conclusive! because! of! the! limitations! of! docking! studies! to! considerate! other!
potential! factors! (i.!e.! rate!of!processing,!stability!etc.)! that!may!be! involved! in!the!
ester!hydrolysis!process.!
Docking9with9Hint"19enzyme9
The! final! step! to! release! of! the!monophosphorylated!NA! inside! the! cells! is!
catalysed!by!Human!triad!nucleotideTbinding!proteins!(Hint).55!They!are!responsible!
for! breaking! the! PTN! bond! between! the! aminoacyl! residue! and! the! phosphate! by!
interaction!of!histidine!residues!in!the!active!site.!Residues!His112,!His!114!and!Ser!
107!are!important!for!the!activity.56!
Docking! studies! with! aminoacyl! phosphoramidate! compound! of! 2T
























In! this! chapter,! a! new!method! for! the! synthesis! of! 2Tchlorocordycepin!was!
developed.! This!method! improved! the! cost! effectiveness! of! the!methods! reported!
previously! in! the! literature.! A! small! family! of! ProTides! was! synthesized! from! 2T
chlorocordycepin! using! three! different! approaches.! The! NMI! approach! using! reT
purified! cordycepin! was! found! to! provide! the! best! yields! in! the! overall! process.!
These! ProTides! as! well! as! the! parent! nucleoside! 2Tchlorocordycepin! were! then!
biologically!evaluated!against!different!cancer!cell!lines.!Cell!viability!assays!showed!
a! general! boost! of! the! activity! of! the! ProTides! in! comparison! to! the! parent!
compound! 2Tchlorocordycepin.! ProTides! 3.9! and! 3.10! were! found! to! be! the!most!




2Tchlorocordycepin! ProTides! are! substrates! for! carboxypeptidase! Y,! and! therefore!
are!being!activated!to!the!monophosphate!species.!It!was!noted!that!for!compounds!
3.9,! 3.13! one! of! their! respective! diastereoisomers! is! more! resistant! against! the!
activation.!Docking!studies!suggested!that!the!S!diastereoisomer!of!ProTide!3.9!could!
be!the!best!processed!by!the!enzyme.!!
To! elucidate! the! resistance! of! the! compounds! against! deamination,! one! of!
the!major!aims!of!the!modifications!to!the!parent!compound!cordycepin,!ADA!essays!
were! performed! on! cordycepin,! 2Tchlorocordycepin! and! compound! 3.9.! The!
experiments!determined!that!the!modifications!performed!in!the!parent!nucleoside!
by! inserting! a! chlorine! substituent! at! position! 2! and! by! ProTiding! position! 5’!
endowed! the! compounds! with! resistance! against! deamination.! However,! the!
resistance!innate!to!2Tchlorocordycepin!was!not!enough!to!exert!anticancer!activity!
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The! second! modification! aimed! to! improve! the! biological! activity! and! the!
stability!of!the!compound!by!changing!the!PTO!bond!between!the!nucleoside!and!the!
phosphate!group!with!a!PTC!bond.!These!alterations!aimed!to!make!the!compound!
































on! different! nucleoside! analogues,! improving! their! activity.1! However,! despite!
promising!in#vitro!activity!results,!none!of!them!has!reached!clinical!trials!yet.!
! In! most! cases! nucleoside! phosphorodiamidates! bear! the! same! amino! acid!
ester!moieties,!which!prevents! the! formation!of! a! chiral! centre! in! the!phosphorus!
atom.! This! provides! an! advantage! in! comparison! to! the! ProTide! because! only! one!
final!compound!is!formed!instead!of!a!mixture!of!diasteroisomers.!
Synthesis9of9Phosphorodiamidates9
Two! different! methods! are! reported! for! the! synthesis! of! symmetrical!
phosphorodiamidates.2! Both! of! them! involve! the! treatment! of! the! nucleoside!
analogue!with!phosphorus!oxychloride!to!obtain!a!nucleoside!phosphorodichloridate!
intermediate.!This!is!typically!monitored!by!31P!NMR!and!gives!a!signal!between!7T8!
ppm,! but! it! is! not! isolated! because! of! its! instability.! The! phosphorodichloridate!







displacing!one!of! the!chlorine!atoms! (a1).! In! the!second!step! (b1),! the! lone!pair!of!
electrons! in! the! amino! group! of! the! aaTester! reacts! with! the! phosphorus! via!





































4.1  R = Benzyl



















substitution! with! a! second! equivalent! of! the! aaTester! then! leads! to! the! final!
compound.1! However,! it! was! reported! that! this! approach! is! sometimes! not!
successful,! either! by! not! achieving! reactivity,! or! by! generating! tetraT








is! very! similar! to! TEA.! This! method! then! furnishes! the! phosphorodiamidate! by!
nucleophilic!substitution!as! in!the!first!approach.!This!strategy!has!been!used!since!
the! first! nucleoside! phosphoramidates! were! reported.4! Phosphoramidate! 4.2! was!






4.19R = Benzyl9 1! 8!%!













Compound! 4.1! was! tested! in! cell! viability! assays.! Detailed! results! can! be!
found!in!Chapter!3.!Figure!4.1!shows!a!graphical!representation!of!the!data.!The!cell!
lines! in!which!4.1!was! tested!were!CCRFTCEM,!MOLTT4,!K562,!HEL92.1.7,!HLT60,!ZT
138,! RL,! HsT445,! RPMIT8226,!MiaTPaTCaT2,! HT29,! HepG2,!MCFT7! and! Cal27.! It! was!
found! that! 4.1! exhibited! enhanced! activity! compared! to! 2Tchlorocordycepin.!
However,! it! was! generally! less! active! than! the! other! synthesised! ProTides! of! 2T
chlorocordycepin!(see!Chapter!3),!except!in!the!RPMI!and!the!MiaTPaTCa!cell!lines.!In!
these!cell!lines!4.1!showed!the!highest!activity!of!the!series.!In!the!RPMI!cell!line!the!





























! The! phosphonodiamidate! strategy! aims! to! increase! the! stability! of! the!
activated! monophosphate! species! towards! enzymatic! dephosphorylation! by!
inserting!a!PTC!bond!between!the!nucleoside!analogue!and!the!phosphate!group.!At!
the! same! time,! phosphonodiamidates! keep! the! prodrug! moieties! of! a!






phosphorus! atom! with! the! sugar! through! a! PTCTO! bond! which! is! isopolar! and!
isosteric! with! the! phosphate! group! PTOTC.5! The! McGuigan! group! is! actively!
investigating! the! influence! of! different! phosphonate! linkers! in! the! ProTide! and!
phosphoramidate!approach.!The!pipeline!of!this!project!include!the!synthesis!of!5’T
methylene!phosphonate,!5’T(E)Tvinylphosphonate,!5’Tfluoromethylene!phosphonate!
and! 5’Tdifluoromethylene! phosphonate.! The! project! is! on! an! early! stage! of!
development!where! the!methylene!bridge!between! the!phosphorus! atom!and! the!
sugar!is!being!explored.!
In! the! literature! the! application! of! the! methylene! bridge! to! mimic! the!
phosphate! bond! in! ribavirin! 5’Tmonophosphate! is! described.! The! new! compound!















































dehydrogenase! and! it! was! considerably!more! stable! to! dephosphorylation.! In! this!
article!Wang!et#al.!encouraged!further!invenstigations.6!
This!part!of!the!chapter!is!focused!on!the!synthesis!of!a!phosphonodiamidate!
of! 2Tchlorocordycepin,! aiming! to! extrapolate! the! synthesis! to! the! aryl!
phosphonamidates! if! it! were! to! show! interesting! activity! after! future! biological!
testing.!
The!strategy!used!for!the!synthesis!of!phosphonamidates!of!NA!has!already!
been!applied! in!acyclic7!and!cyclic!nucleosides,! the! latter!was!recently! improved! in!

















! Protection! of! the! hydroxyl! groups!with! TBDMSCl! to! obtain! compound!3.18!
was! performed! following! the! best! yielding! method! described! in! Chapter! 3! using!
imidazole!and!DMF.!As! it!was!previously!discussed,!the!TBDMS!group!was!selected!
because!it!can!be!selectively!cleaved!from!primary!alcohols!without!affecting!other!
functionalities.! Then,! a! bisTtertTbutyloxycarbonyl! (BOC)! protection! of! the! amino!
group! was! performed! using! DMAP! as! catalyst,! delivering! compound! 4.3! in!
quantitative!yield.!The!lone!electron!pair!of!the!nitrogen!in!the!pyridine!ring!attacks!
one! of! the! carbonyl! groups! of! the! BOC2O,! forming! an! intermediate! with! a! good!
leaving! group! that! can! then! be! further! attacked! by! the! primary! amine! in! the!







































































































acid! (CSA)! delivered! compound! 4.4! in! quantitative! yields.! Compound! 4.4! was!
suitable!to!undergo!the!procedure!by!Seamon!et#al.!In!the!first!step,!treatment!of!4.4!
with! freshly! prepared! 2TIodoxybenzoic! acid! (IBX)! (prepared! according! with! the!







Next,! a! HornerTWadsworthTEmmons! reaction! formed! the! diethyl! ethenyl!






























































































unstable! and! leads! to! the! formation! of!4.6! via! elimination! of! the! oxygen! (Scheme!
4.7).!Overall!yield!from!4.4!to!4.6!was!52!%.!
! Catalytic! hydrogenation! using! 10! %! Pd/C! then! reduced! the! phosphonate!
double!bond!of!compound!4.6,!leading!to!compound!4.7.!This!reaction!yielded!65!%!
after! purification! by! column! chromatography.! Next,! the! protecting! groups! of! the!
amine! at! 4! and! hydroxyl! at! 2’!were! removed! by! applying! a!mixture! THF,!H2O! and!
formic! acid! (1:1:2)! and! stirring! for! 72! h! at! 30! ˚C,! to! furnish! the! unprotected!
compound!4.8!in!58!%!yield.!
! Finally,! the!one!pot! reaction! to!obtain! the! final! compound!was! initiated.! In!
the! first! step,! reaction! of! 4.8! with! TMSBr! delivered! the! bisTsilylated! phosphonate!
ester! 4.8a.! 2,6TLutidine! was! used! as! a! mild! base! to! prevent! degradation! of! the!
product! during! the! reaction! because! of! the! bromhidric! acid! forming! during! the!
silylation.! The! crude!of! the! reaction!was!evaporated!and!dissolved! in!pyridine!and!
triethylamine.! The! second! part! of! the! reaction! took! place! following! a! reaction!
mechanism! that!was!elucidated!by!Mukaiyama!et#al.! in!1971.14! In! a! separate! flask!
aldrithiolT2! and! triphenylphosphine! (Ph3P)!were! dissolved.! The! phosphorus! attacks!
one!of!the!sulphur!atoms!of!aldrithiolT2,! leading!to!an!anion!of!2Tmercaptopyridine!
4.10!and!a!cation!of!triphenylphosphine!2Tmercaptopyridine!4.11.!The!sulphur!atom!


































































4.8c.! Meanwhile! compound! 4.10! reacts! with! the! aaTester! deprotonating! it.! The!
negatively!charged!amine!of!the!aaTester!reacts!with!the!phosphorus!of!intermediate!
4.8c!leading!to!a!monophosphonamidate!compound.!Finally!the!amino!group!of!the!
aaTester! will! attack! the! phosphorus! of! intermediate! 4.8c! leading! to! the! desired!
phosphonodiamidate!compound!4.8d.!This!process!repeats!to!create!compound!4.9!
with! 3! %! overall! yield.! (Scheme! 4.8).! Optimisation! of! the! last! reaction! would! be!




































































of! 2Tchlorocordycepin! were! explored.! The! first! strategy! was! to! apply! the!
phosphorodiamidate! approach,!which! is! a! variation! of! the! ProTide! approach.! Two!
compounds! 4.1! and! 4.2! were! synthesised! using! two! different! synthetic! methods.!
Compound! 4.1! was! tested! against! a! wide! sample! of! cancer! cells! proving! that! it!
enhanced! the! activity! of! the! parent! nucleoside.! Indeed,! it! showed! better! activity!




phosphonodiamidate! 4.9! was! developed.! However,! this! sevenTstep! synthesis! will!
require!optimisation! in! the! last! step,!which!only!delivered!3!%!yield.!On! the!other!
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3’"Ethynyl9 nucleoside9 analogues9 –9 Rationale9 behind9 the9
design.9
! In! 1996,!Matsuda! et# al.! aimed! to! synthesise! a! NA!with! antitumour! activity!





! To! design! RNA! synthesis! antimetabolites,! they! decided! to! keep! the!
riboconfiguration!with!both!hydroxyls!at!the!2’!and!3’!positions,!so!the!NA!could!be!
recognised! by! the! RNA! synthetic! enzymes! to! either! exert! inhibition! or! to! undergo!
metabolic! transformations! such! as! phosphorylation,!
since!they!considered!that!the!triphosphate!form!would!
be!required!to!inhibit!RNA!Polymerases.1,2!
To! inhibit! DNA! synthesis,! they! chose! to! target!
Ribonucleoside! diphosphate! reductase! (RR),! which!
catalyses! the! conversion! of! ribonucleoside! 5’T
diphosphate! to! their! corresponding! 2’T
deoxyriborucleoside! 5’Tdiphosphates! in! the! de# novo!
pathway.1,2! Stubbe! et# al.! (1980)! postulated! that! the!
mechanism! of! this! reaction! would! be! initiated! by! the!
























Figure' 5.1:#Uhlin# et# al# (1994).# Schematic#
drawing# of# the# active# site# region# of#
subunit# R1# of# ribonucleotide# reductase,#
with# a# model# derived# plausible# position#
for# a# substrate#molecule.# # The# proximity#
between# Cys439# and# H# at# 3’# of# the#
ribonucleotide# can# be# clearly# seen.4'
Reprinted# with# permission# from#
Macmillan# Publishers# Ltd:# Uhlin# et# al.#





by! a! µToxo! bridged! binuclear! iron! (III)! centre! to! 3’! hydrogen! atom! of! the!




diphosphate! nucleoside! could! form! a! bond! with! the! thiol! of! Cys! 439! in! an!
alkylthiovinyl! sulphide! through! a! radical! reaction,! and! therefore! inactivate! the!
enzyme.1,2!
Following! this! reasoning! they! first! synthesised!3’Tethynyl!uridine! (EUrd)!5.1,!
and,! after! achieving! submicromolar! EC50! values! in! in# vitro! cytotoxicity! tests,1! they!
enlarged! the! family! by! synthesising! 3’Tethynylcytidine! (ECyd)! 5.2,! 3’Tethynyl! 5T
methyluridine! (EMUrd)!5.3,! 3’TethynylT5TfluoroTcytidine,!3’TethynylT5TfluoroTuridine,!
3’TethynylTadenosine!and!3’TethynylTguanosine.2! ECyd!and!EUrd!achieved! the!most!
promising! in# vitro# results! in! various! solid! tumour! cell! lines! and! experiments! on!





explored! the! length! required! between! C3’! and! the! ethynyl! group.! Therefore,! they!
prepared! ECyd! and! EUrd! analogues! bearing! other! 3’! substituents:! 1TPropynyl,! 2T
propynyl,! 1Tbutynyl,! ethenyl,! ethyl! and! cyclopropyl.! 1Tpropynyl! and! ethenyl!
substituents!displayed!some!activity,!but!it!was!1500!to!520Tfold!lower!than!ECyd!or!
EUrd.8! Then,! the! role! of! 3’! hydroxyl! was! investigated! and! 3’TdeoxyTECyd! and! 3’T
deoxyTEUrd! were! synthesised! but! the! compounds! lacked! activity.8! They! next!
questioned!the!importance!of!the!configuration!at!position!3’!by!inserting!an!ethynyl!
and! 2Tpropynyl! substituent! in! the! αTposition! of! the! riboT! and! 3’! deoxyribo!
configuration! of! uridine! and! cytidine.! Again,! those! substitutions! delivered! inactive!
compounds.8!They!also!explored!shifting! the!ethynyl! substituent! to!position!2’!and!








group! inspired!by!Matsuda’s!work! reviewed!and! synthesised!other! ECyd! and!EUrd!
analogues! with! modifications! in! their! pyrimidine! nucleobases.! The! best! tolerated!
modifications!were! CT5! halogen! substitutions!with! iodine! and! fluorine! but! activity!
was!20!−!50!times! lower!than!that!of! the!parent!nucleosides.!They!also!noted!that!
nucleosides! with! 5Thydroxyuridine! and! 3Tdeazauridine! bases,! which! showed! no!
activity,! had! a! better! cytotoxic! profile! without! the! 3’Tethynyl! substituent.9! SAR!
studies!showed!that!the!ethynyl!group!has!the!adequate!length!and!that!it!has!to!be!
positioned!in!the!βTconfiguration!at!the!3’!position!for!the!best!fit!and!thus!elicitation!
of! activity.! The!presence!of! the!hydroxyl! groups!at! 2’! and!3’!was! found! to!be!also!
important!for!the!activity,!since!the!compounds!are!mainly!RNA!inhibitors!and!need!
to!be! recognised!by! the!enzymes! in!charge!of!RNA!synthesis,!as!RNA!polymerases.!
The! substitution! of! the! oxygen! at! position! 4’! by! a! sulphur! atom! was! not! well!
tolerated! for! the! anticancer! activity,! but! it! delivered! compounds! with! antiviral!
activity.! Cytidine! and! Uridine! were! the! best! tolerated! nucleobases! for! these!
compounds!
Studies! on! the!mechanism! of! action! of! ECyd! and! EUrd! revealed! that! their!
biological! activity! depends! on! their! phosphorylation.! The! active! form! of! those! NA!
was!identified!to!be!ECydT5’Ttriphosphate!(ECydTTP)!and!EUrdT5’Ttriphosphate!(EUrdT
TP),!and!the!enzyme!responsible!for!their!phosphorylation!is!uridineTcytidine!kinase!
(UCK).10! Two! isoforms!of!UCK!were! identified:!UCK1! and!UCK2.! ! It!was! found! that!
ECyd! and! EUrd! might! be! preferentially! phosphorylated! by! UCK2.11,12! The!
phosphorylation! by! UCK! was! found! to! be! upregulated! in! tumours,! which!
phosphorylated! ECyd! 20T30Tfold! more! than! in! nonTcancerous! tissues,13! probably!
because! of! higher! expression! of! UCK! in! tumour! tissues! than! in! nonTneoplastic!
tissues.14! Although! the! phosphorylation! of! both! ECyd! and! EUrd! happens! very!




ECydTTP! and! EUrdTTP! are! not! efficiently! dephosphorylated,! so! they! overcome! one!
important!catabolic!process!that!endows!them!with!a!long!half!life.10!
Interestingly,!cells!treated!with!EUrd!accumulated!both!EUrdTTP!and!ECydTTP.!
This! suggested! an! efficient! conversion! inside! the! cell,! probably! by! cytidineTTP!
synthase.15!However,!very!small!amounts!of!EUrdTTP!were!found!in!cells!treated!with!
ECyd,! indicating! some! resistance! of! ECyd! towards! deamination.! This! was! an!
important! in! the! consideration! to! choose! ECyd! over! EUrd! as! the! drug! to! proceed!
(Figure!5.2).15!
!
Furthermore,! it!was! revealed! that! the!diphosphate!of!ECyd!or!EUrd!did!not!
inhibit!RR,13!and! that! the!biosynthesis!of!endogenous!nucleoside! triphosphate!was!
not!affected.10!
However,!ECydTTP!and!EUrdTTP!proved!to!be!potent!RNA!inhibitors,!acting!as!
nonTselective! competitive! inhibitors! of! RNA! polymerases! I,! II,! and! III! during! RNA!
transcription.10!ECydTTP!binds!to!RNA!polymerase!with!380!times!higher!affinity!than!
cytidineTTP,15! and! through! that! inhibited! over! 80T90! %! of! the! RNA! synthesis! in!
tumour! cells,15! resulting! in! cell!death.16! Some! inhibition!of!DNA!synthesis!was!also!
observed!and! it!was!probably!secondary! to! the!potent! inhibition!of!RNA!synthesis.!
ECyd! inhibits! cell! growth! in! cells! by! the! inhibition! of! RNA! synthesis.10! Other!
secondary! mechanism! of! actions! that! were! recently! discovered! for! these!
compounds,! specifically! ECyd,! involve! the! induction! of! G2/M! arrest! that! leads! to!
apoptosis,17!and!the!downregulation!of!TIGAR!(an!apoptotic!regulator).17!
ECyd! and! EUrd! have! also! shown! activity! towards! cancer! cells! which! had!









ECyd! downTregulated! the! expression! of! BRCA2! after! XTray! irradiation.! BRCA2! was!
identified! as! responsible! for! repairing! damaged! DNA.! Although! the! precise!
mechanism!still!remains!unknown,!this!suppression!enhanced!the!radiosensitivity!of!
the!tumour!cells!and!may!therefore!result!in!a!better!effectivity!of!radiotherapy!for!
solid! tumours.20! In!addition,!ECyd!also!proved!to!be!a! radiosensitiser!by!enhancing!
the! protonTinduced! cell! death! in! proton! beam! therapy.! The! involved!mechanisms!
remain!unclear,!but!seem!to!differ!from!those!observed!for!XTray!irradiation.21!
As!mentioned!before,!ECyd!was!eventually!carried!forward!to!being!studied!
in!preclinical! and! clinical! trials.! Preclinical! trials! in!nude! rat!models!bearing!human!
tumours! showed! strong! antitumour! activity! without! serious! toxicity.! Furthermore,!
ECydTTP! was! retained! in! tumour! tissue! at! high! intracellular! concentrations! for!
prolonged!periods,!but!not! in!nonTtumour! tissue.!Those! results!encouraged!clinical!
trials.22!





event! occurred! in! treated! patients.25! Furthermore,! a! combination! of! ECyd! and!
carboplatin!entered!in!phase!I!trials!and!showed!to!be!well!tolerated.!However,!even!
though! the! patients! did! achieve! neither! complete! nor! partial! response,! this!
combination!will!proceed!to!phase!II.26!







to! be! the!main!mechanism! of! resistance,! but! altered! cell! permeability! (increasing!
efflux! and! decreasing! uptake)! might! also! have! played! a! role.10,12! In# vitro! data!
anticipated! that! the! ECyd! and! EUrd! resistant! cells! lacked! UCK,10,12! in! particular!
isoform! UCK2.17! In# vitro! testing! further! identified! that! resistant! cells! to! ECyd! and!
EUrd!had!modifications! in! the!genes!encoding!UCK2,! and! that!while! its! expression!
was! decreased,! UCK1! encoding! genes! and! expression! remained! unaltered! in! the!
same!resistant!cells.17!
The! objective! in! this! chapter!was! the! synthesis! of! a! small! families! of! ECyd,!
EUrd! and! EMUrd! ProTides! with! antiTcancer! properties! that! may! overcome! the!
resistance!mechanisms!directed!against! their!parent!nucleosides,! since! they!would!
not! require! UCK! for! initial! phosphorylation.! While! this! project! was! in! progress,! a!
patent!was! filed! in!China!exemplifying! two!ECyd!ProTides,! bearing! isopropyl,L,AlaT
Phenyl! and! Benzyl,L,AlaTPhenyl! moieties.28! Shortly! after! that,! Idenix!
Pharmaceuticals,! Inc.!exemplified!generic!EUrd!and!ECyd!ProTides!bearing!D!amino!







Among! the! reported! syntheses! of! 3’Tethynyl! nucleosides,! the! procedure! by!
Nomura! et# al.! (2001)! was! chosen.! They! reported! an! optimized! pathway! for! the!
synthesis!of!ECyd!and!EUrd,!exploring!different!conditions!that!aimed!for!good!yields!
and! crystalline! intermediate! compounds.30! Scheme! 5.2! shows! the! selected! sevenT
step!synthesis.!
!
! The! synthesis! used! 1,2TOTisopropylideneTDTxylofuranose! 5.4! as! starting!
material,!which! is!commercially!available.! In!the!first!step,!the!hydroxyl!group!at!5’!
would!be!protected!(a).!Among!the!reported!protecting!groups,!4TChlorobenzoyl!(4T






















































































the! chosen! protecting! group! was! once! again! 4TClBz! because! it! was! reported! to!
deliver! compound! 5.9! as! a! precipitate! that! could! be! collected! by! filtration.! A!
Vorbrüggen! reaction! for! the! coupling! of! the! sugar! 5.9! and! the! base! would! be!
performed!with!SnCl4!(a!Lewis!acid)!using!previously!bisTsilylated!Uracil!(e).!Finally,!a!
deprotection!of!all!protecting!groups!from!5.10!would!lead!to!the!desired!compound!
EUrd! 5.1.! Once! optimised,! this! methodology! was! planned! to! be! applied! for! the!
synthesis!of!ECyd!and!EMUrd.!
First9approach:9R19H;9R294"ClBz9
The! protection! of! 1,! 2TOTisopropylideneTDTxylofuranose! 5.4! with! 4TClTBzTCl!
achieved!compound!5.59 in!47!%!yield.!The!hydroxyl!group!at!position!5’!in!the!sugar!
would! react! with! the! carbonyl! group! in! a! nucleophilic! substitution,! cleaving! the!
chlorine.!
Optimisation!of! the!oxidation!of! the!3’Thydroxyl!group! to!obtain!compound!
5.6!was!required.!In!the!first!attempt!2,2,6,6TtetramethylpiperidinylT1Toxy!!(TEMPO)!
was!used!as!a!catalyst!and!NaOCl!as!a!coToxidant.!As!shown! in!Scheme!5.3,!during!
the! process,! a! catalytic! amount! of! NaOCl! oxidises! the! TEMPO! radical! (i)! to! the!NT
oxoammonium! ion! (ii),! which! then! oxidises! the! secondary! alcohol! at! 3’! giving! a!
molecule!of! the! corresponding!hydroxylamine! (iv).! This! intermediate! can!either!be!







Unfortunately,! in! this!work,! this! reaction!did!not!deliver!compound!5.6!and!
other!mechanisms!of!oxidation!were!investigated.!
Dess! Martin! Periodinane! (DMP)! is! a! hypervalent! iodine! compound! that!
performs! a! selective! and!mild! oxidation! of! alcohols! to! aldehydes! or! ketones.! The!
alcohol!attacks!the!iodine!atom,!which!is!very!electropositive!due!to!the!surrounding!
environment!of!electronTwithdrawing!groups.!One!of!the!acetoxy!groups!then!leaves!
the!molecule!as!a!good! leaving!group.!Then,! the!negatively! charged!oxygen!of! the!
acetoxy!group!accepts!the!hydrogen!from!the!CH!in!the!secondary!alcohol.!Electrons!




yielding! from!40! to!96!%! (Table#5.1).!When! lower!yields!were!achieved,!unreacted!






























































It!was! found!that! 4JH,H! couplings!can!be!observed! in!saturated!systems! if! there! is!a!
proper!orbital!alignment!between!CTH!bonds!and! intervening!CTC!bonds.!The!most!
favourable!alignment!is!a!“W”!arrangement!of!the!connecting!bonds.!Therefore,!it!is!
expected! that! the! conformation! acquired! of! 5TOT(4Tchlorobenzoyl)T1,2TOT
isopropylideneTDTerythroTpentofuranoseT3Turose! (5.6)! would! be! close! to! a! “W”!
arrangement.!!
The!introduction!of!an!ethynyl!group!in!βTconfiguration!to!obtain!compound!
5.7! was! achieved! using! CH≡CMgBr! in! THF! at! 0! ˚C.! The!Grignard! reaction!with! the!
ketone!is!postulated!to!happen!through!a!six!membered!ring!transition!state!of!the!
ketone!with!two!molecules!of!CH≡CMgBr!(Scheme!5.6).36!
Comp.9 Attempt9 Reagent9 5.59(g)9 Yield9 Purification9




5.699 B! DMP9 0.4079 40!%! CC9
5.699 C! DMP9 2.09 96!%! Precipitation9
5.699 D! DMP9 6.59 88!%! Precipitation9
5.699 E! DMP! 10.53! 54!%! CC!




















! It! is! reported! that! this! reaction! delivers! exclusively! the! 3’TβTethynylT3’TαT
hydroxyl!product.30! Indeed,! the! reaction!delivered!only!one!product!whose! 1H!and!




The! stereochemistry! of! 5.7! was! confirmed! by! 2D! nuclear! Overhauser!
enhancement! spectroscopy! (NOESY)! experiment.! The! most! relevant! region! of! the!
NOESY!spectrum!is!expanded! in!Figure!5.4.!The!correlation!between!the!3’TOH!and!
4’TH!indicated!their!spatial!proximity,!and!thus,!that!both!protons!were!on!the!same!




































!! Deprotection!of! the!hemiacetal! group! in!acidic! conditions! in! compound!5.7!
was! performed! using! a! mixture! of! formic! acid! (HCOOH)! and! water! 1:1! at! reflux!
temperature.!The!resulting!compound!5.8!is!a!mixture!of!isomers!where!the!hydroxyl!
group!at!position!1’! is!either! in!α!or!βTconfiguration.!This! is!due!to!the!equilibrium!
between!the!cyclic!and!linear!forms!of!the!ribose!ring!(Scheme!5.7).!
!
! The! hydroxyl! groups! of! compound! 5.8! were! individually! protected! by! 4T
chlorobenzoyl! chloride! (4TClBzCl)! to! achieve! compound! 5.9.! 4T
(Dimethylamino)pyridine! (DMAP)!was! used! as! a! catalyst! for! the! reaction! and! Et3N!
was!used!as!an!auxiliary!base!to!regenerate!the!activated!form!of!DMAP.!During!the!
process! DMAP! reacts! with! 4TClBzCl! in! an! equilibrium! forming! an! acylpyridinium!
cation! as! intermediate.! The! oxygen! in! the! hydroxyl! group! reacts! with! this!





















































The! characterization! of! the! individual! isomers!was!made! by! comparing! the!




Karplus!equation!because! those!protons!should!adopt!a! torsion!angle!close! to!90˚.!






































The! formation! of! the! N! glycosidic! bond! was! performed! via! Vorbrüggen!
procedure.38!This!rateTlimiting!reaction!required!a!silylated!base!at!position!2!and!3,!
which! was! achieved!with! hexamethyldisilazane! (HMDS)! and! a! catalytic! amount! of!
ammonium!sulphate.!Scheme!5.10!illustrates!the!putative!mechanism!of!action.!The!
protected!sugar!5.9!reacts!in!the!presence!of!SnCl4!by!forming!a!cyclic!intermediate!
of! a! 1,2Tacyloxonium! salt.! The! resulting! stereochemistry! of! the! intermediate!
compound! depends! on! the! stereochemistry! of! the! CT2’,! delivering! the! 1,2T
acyloxonium!cation! in!the!αTside!of!the!sugar.!This!reaction! is! favoured!because!of!
the! electrophilicity! of! CT1’,! with! two! neighbour! oxygen! atoms.! Next,! the! released!
chlorine! anion! attacks! the! silylated! base! at! position! 2! (the! most! electropositive),!
which!simultaneously!attacks!the!sugar!cation!at!position!1’!(the!most!electrophilic)!
from! the! beta! side! of! the! sugar! to! form! the! nucleoside! in! the! opposite! side! The!
remaining!TMS!group!is!then!being!released!by!the!acidic!workTup.39!
!




Finally,! the! deprotection! of! the! 2’,! 3’! and! 5’! hydroxyl! groups! with! 1,8T
diazabicycloundecT7Tene! (DBU),! a! nonTnucleophilic! base,! removed! the! protecting!





















































introduction! of! the! ethynyl! group,! which! is! inserted! on! compound! 5.6! by! the!
Grignard! reagent! TMSTC≡CMgBr.! This! reagent! was! generated! in# situ! by! reacting!
trimethylsilylacetylene!with!ethylmagnesiumbromide!(EtMgBr).!A!six!membered!ring!
transition! state! leads! to! the! introduction! of! the! TMSTethynyl! group! in! beta!
configuration.36! The! formation! of! the! resulting! compound!5.11! was! achieved!with!




as! the! protection! with! 4TClBzCl! and! gave! quantitative! yields! of! compound! 5.13.!
Isomers!α!and!β!were!also!obtained!in!an!8:2!proportion!and!were!used!for!the!next!
step! without! further! separation.! As! explained! above,! assignment! of! the! signals!
corresponding! to! the!α! and!β! isomers!was! possible! by! comparison!with! literature!
data.!Indeed,!the!main!characteristics!remained!the!same!as!for!the!4TClBz!protected!
sugar.!!
The! glycosylation! reaction! with! silylated! uracil! led! to! compound! 5.149 and9
yielded! 50T61! %,! which! was! a! more! than! 3Tfold! increase! compared! to! the! 1st!







Table# 5.2! shows! the! comparison! of! the! best! yields! achieved! in! every! step!
between!the!first!and!second!approach.! In!most!of!the!steps,!the!second!approach!
delivered!better!yields,!resulting!in!an!overall!yield!that!was!4!times!greater!for!the!




9 Step!a!+b! Step!c! Step!d! Step!e! Step!f! Step!e! Overall!
First9approach9
Scheme95.29
45!%! 65!%! 95!%! 45!%! 20!%! 87!%! 2.2!%!
Second9approach9
Scheme95.119




























































































































Once! the!method! to! synthesise! EUrd! had! been! optimised,! the! synthesis! of!
the!other!pyridine!base!nucleosides!was!performed!as!shown!in!Scheme!5.11.!
A! Vorbrüggen! reaction! to! couple! intermediate!5.13! with! either! cytosine! or!
thymidine!was!performed!(steps!h!and!j)!followed!by!deprotection!with!DBU!(steps!i!
and! k).! Vorbrüggen! reaction! delivered! protected! 3’Tethynylcytidine!5.15! in! a! 45!%!
yield.!Deprotection!with!DBU!then!afforded!the!desired!compound!5.2!with!a!42!%!
yield.! Vorbrüggen! reaction! with! thymine! delivered! protected! 3’TethynylT5T
methyluridine! 5.16! in! a! 48! %! yield.! Deprotection! with! DBU! afforded! desired!
compound!5.3!with!an!89!%!yield.!Using!this!optimised!pathway,!similar!reactivity!for!


























was! performed! at! 30! ˚C,! and! no! precipitate! was! observed.! The! reactions! yielded!




the!aqueous!phase,!owing! to! its!hydrophilic!nature.! It!was!not!possible! to! recover!
the! compound.! Thus,! the! compounds! were! directly! purified! by! flash! column!
chromatography.! Remaining! NMI! was! removed! by! purifying! the! compound! two!
times!using!preparative!TLC.!!
9Table95.4:9Summary!of!the!coupling!reactions!performed!on!EUrd!5.1.931P!NMR!spectra!recorded!in!MeOD.!
Compound9 5.19 Yield9 31PNMR9(ppm)9
5.179 158!mg9 7!%9 4.07,!3.72!
5.189 100!mg9 13!%9 3.63,!3.41!
5.199 100!mg9 11!%9 4.35,!4.20!
5.209 56!mg9 Traces9 T!
5.219 100!mg9 7!%9 3.61,!3.33!
5.229 143!mg9 9!%9 3.63,!3.41!
!
!












only! very! low! reactivity! was! observed! (Table# 5.5),! varying! from! no! reaction! at! all!
(compound! 5.25)! to! 1T3! %! yield.! Compounds! 5.23! and! 5.24! were! isolated! for!




Compound9 5.29 Yield9 31PNMR9(ppm)9
5.239 383!mg! 1!%! 3.27,!3.42!
5.249 184!mg! 3!%! 3.72,!3.52!
5.259 90!mg! No!reaction! T!
! !
Therefore,!a!different!approach!was!designed!to!synthesise!ECyd!ProTides.!To!
improve! reactivity,! tBuMgCl! was! considered! as! stronger! base! for! the! coupling!
reaction.!To!avoid!side!reactions!forming!bis!or!tri!ProTides!and/or!2’,!or!3’!ProTides,!









with! 500! mg! of! 5.2,! observing! very! poor! solubility! of! the! compound! in! acetone.!
Compound!5.26!was!obtained!in!26!%!yield.!Next,!the!coupling!reaction!tBuMgCl!and!








































































Compound9 5.39 Yield9 31PNMR9(ppm)9
5.289 345!mg! 2!%! 3.60,!3.36!
5.299 192!mg! 9!%! 3.53,!3.26!
5.309 345!mg! 9!%! 3.63,!3.32!
5.319 240!mg! 15!%! 3.64,!3.35!










assay.! It! was! performed! by! WuXi! AppTec! to! assess! the! cytotoxic! activity! of! the!
prodrugs!in!comparison!to!their!respective!parent!nucleosides,!using!paclitaxel!as!a!
control!compound!(Table#5.7).!!



















Therefore,! basing! our! study! on! previous! results! by! Hattori! et# al.! the! selected! cell!
lines! for! this! study! come! from! the! same! tissue!where! EUrd! and! ECyd! showed! the!
highest!cytotoxic!activity.!The!chosen!tissues!were!from!leukaemic,!pancreas,!colon,!




















part.! Half! maximal! effective! concentration! (EC50)! and! Top! Inhibition! percentage!





Leukaemia! Pancreas! Colon! Liver! Breast! H&N! Glioblastoma!
MOLTT4!! MiaTPaTCaT2! HT29! HepG2! MCFT7! Cal!27! T98G!
EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%!
EUrd9 <0.1! 99! <0.1! 99! 0.1! 83! 0.3! 80! 0.9! 92! 0.5! 101! 1.8! 86!
ECyd9 <0.1! 99! <0.1! 99! 0.1! 84! 0.1! 80! <0.1! 90! 0.1! 99! 0.7! 84!
EMUrd9 >198! T9! >198! 35! >198! 35! >198! 29! >198! T2! >198! 9! >198! 6!
!
EMUrd! was! totally! inactive! in! the! tested! cell! lines.! At! the! maximum!
concentration!(198!µM),!it!inhibited!a!maximum!of!35!%!of!the!cells!in!pancreas!and!
colon.! The! inactivity! was! also! translated! in! the! predicted! EC50! values,! which!were!
higher! than! the! maximum! tested! concentration.! This! was! expected,! as! this!
compound!did!not!show!any!inhibitory!effect!in!the!past!when!it!was!tested!in!other!
cell! lines.2.! It! was! suggested! that! EMUrd! was! not! recognised! by! the! putative!
activating!enzymes!such!as!uridine/cytidine!kinase,!because!of!the!bulky!substituent!









inhibition! percentages! (above! 80! %),! and! the! activity! characterised! by! EC50! was!
found! to! be! subTmicromolar! (ranging! from! 0.02! µM! to! 0.95! µM),! except! for! the!
activity!of!EUrd!on!T98G!that!reached!1.79!µM.!Both!showed!similar!activity!in!most!




Table!5.10! compares! the!EC50! values!obtained! in! this! assay!with! the! values!























EUrd9 <0.1! 0.054! 0.1! T! 0.9! 0.20!



















active! ProTides! were! found! to! be! 5.17! (Neop,L,AlaTNaph,! LogP! =! 3.34)! and! 5.21!







In! the!best!case,! the!activity!was!equal! to! the!parent!nucleoside!as! for!5.17! in!cell!
line!MCFT7,!but!the!EC50!values!were!generally!higher!by!one!order!of!magnitude.!!





Leukaemia! Pancreas! Colon! Liver! Breast! H&N! Glioblastoma!
MOLTT4! MiaTPaTCaT2! HT29! HepG2! MCFT7! Cal!27! T98G!
EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%!
EUrd9 <0.1! 99! <0.1! 98! 0.1! 83! 0.2! 80! 0.9! 92! 0.5! 101! 1.8! 86!
5.179 2.9! 102! 0.2! 99! 1.2! 97! 0.7! 98! 0.8! 96! 1.1! 101! 5.3! 91!
5.189 0.3! 100! 1.8! 102! 1.7! 91! 6.2! 92! 7.4! 97! 7.1! 103! T! T!
5.199 0.4! 100! 1.2! 100! 1.0! 88! 3.3! 88! 3.0! 95! 2.2! 102! T! T!
5.219 0.3! 99! 0.7! 102! 0.8! 86! 1.8! 85! 2.9! 95! 2.7! 102! T! T!
5.229 59.8! 94! 8.8! 98! 10.9! 92! 9.8! 94! 29.9! 85! 28.9! 97! 75.0! 71.2!









MOLTT4!! MiaTPaTCaT2!HT29! HepG2! MCFT7! Cal!27! T98G!
EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%!
ECyd9 <0.1! 99! <0.1! 99! 0.1! 84! 0.1! 80! <0.1! 90! <0.1! 99! 0.7! 84!
5.239 57.8! T1! 3.3! 97! 7.2! 84! 4.3! 94! 4.5! 96! 4.5! 100! 87.0! 60!
5.249 7.3! 1! 0.3! 100! 0.8! 100! 0.8! 100! 0.5! 100! 0.7! 100! 10.9! 99!
Paclitaxel90.006! T5.8! 0.003! 85! 0.004! 80! 0.075! 54! 0.003! 81! 0.002! 97.75! 0.008! 87!
!






showed!activity!one!order!of!magnitude!worse! than!5.24.! The!cell! lines!where! the!
ProTides!showed!highest!activity!was!as!follows,!in!descending!order:!MiaTPaTCaT2!>!
MCFT7!>!Cal!27!>!HepG2!>!HT29!>!MOLTT4!>!T98G.!




MOLTT4!! MiaTPaTCaT2! HT29! HepG2! MCFT7! Cal!27! T98G!
EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%!
EMUrd9 >198! T9! >198! 35! >198! 36! >198! 29! >198! T2! >198! 9! >198! 6!
5.289 >198! 1! >198! 38! >198! 13! >198! 4! >198! 24! >198! 18! >198! 3!
5.299 32.1! <1! 7.0! 94! 11.2! 75! 16.5! 65! 22.8! 72! 19.5! 93! >198! 42!
5.309 81.5! 2! 21.4! 69! 182.2! 58! >198! 50! 61.2! 68! 72.7! 70! >198! 31!
5.319 >198! 5! >198! 15! >198! 10! >198! 8! >198! 19! >198! 17! >198! 9!





Here,! the! ProTides! were! found! to! be! not! as! active! as! in! the! previously!
discussed!families.!In!most!cases,!they!did!not!reach!high!levels!of!top!inhibition.!The!
ProTides!5.28! and9 5.31! totally! lacked! activity.! Poor! activity!was! displayed! by!5.30,!





The! best! compounds! of! each! family! in! comparison! with! their! respective!
parent!nucleoside!are!displayed!in!Table#5.14.!Interestingly,!they!all!bear!hexyl,L,AlaT
phenyl!moieties!(5.21,!5.24!and!5.29)!and!are!also!among!the!most!lipophilic.!It!will!
require! further! investigation!to!analyse! if! the!activity! is! related!to!the!specificity!of!
the!substituent!or!to!the!physicochemical!characteristics.! !
Table9 5.14:9 Comparison! of! the! EC50! (µM)! of! the! best! performing! ProTides! of! each! family,! and! their! parent!
nucleotide!
!
MOLTT4! MiaTPaTCaT2! HT29! HepG2! MCFT7! Cal!27! T98G!
3'EUrd9 <0.1! <0.1! 0.1! 0.3! 0.9! 0.5! T!
5.219 0.3! 0.7! 0.8! 1.8! 3.0! 2.7! T!
3'ECyd9 <0.1! <0.1! 0.1! 0.1! 0.1! <0.1! 0.7!
5.249 7.3! 0.3! 0.8! 0.8! 0.5! 0.7! 10.9!
3'EMUrd9 >198! >198! >198! >198! >198! >198! >198!





from!a!nonTactive!nucleoside! analogue.!5.21! and!5.24! showed!a! similar! activity! as!
their!parent!nucleoside!in!cell!lines!HT29,!HepG2!and!MCFT7.!However,!even!if!they!
did! not! enhance! the! activity! of! their! two! very! active! parent! nucleosides,!5.21! and!
5.24! were! the!most! active! among! all! the! investigated! families.!5.21! was! found! to!




ProTides! was! similar! and! for! the! rest! of! the! cells! the! activity! of! 5.24! was! higher.!
(Figure!5.7)!
!
It! is!worth!noting!here! that!even! if! ECyd!had!a!very!high! in# vitro! activity,! it!
performed! very! poorly! in! clinical! trials.25! As!mentioned! before,! those! results!were!
attributed!to!the!resistance!of!cancer!cells!towards!3’Tethynyl!nucleosides!because!of!







a! recent! publication! that! identified! EUrd! in! a! broad! screening! to! be! active! against!
temozolidineTresistantTglioblastomaTinitiating!cells.19! It!was!not!possible! to! test!our!
compounds!in!that!specific!cell!line,!so!T98G!was!selected!for!the!test.!EUrd!showed!
an! EC50! of! 1.79!µM! and! ECyd! showed! an! EC50! of! 0.75!µM! for! this! cell! line.! EUrd!

















obtain! preliminary! results.! Since! the! activity! of! the! parent! nucleoside! and! the!
ProTide!was!comparable,! it!could!be!possible!that!the!activity!could!also!be!similar!










tested!in!a!carboxypeptidase!Y!enzymatic!assay!(Table#5.15!).! This! assay! aimed! to!










The! experiment! was! performed! as! described! in! Chapter! 3! and! the!
experimental! chapter,! by! dissolving! the! compound! in! deuterated! acetone! and!
recording! the! spectrum! to! set! the! blank! reference.! After! the! addition! of! the!
Carboxypeptidase!to!the!sample! in!TRIZMA!buffer!at!pH!7.6!and!25!˚C,!mutiple!31P!
NMR!spectra!were!recorded!periodically! for!13!hours.!Shifts! in! the!signal! indicated!
the!formation!of!new!species.!
Two! intermediate! compounds! are! often! observed! in! this! experiment:! The!
phosphoramidate!after!the!cleavage!of!the!ester!moiety!(usually!showing!two!signals!
around! 4T5! ppm),! and! the! aminoacyl! phosphoramidate! intermediate! after! the!
subsequent! cleavage!of! the!aryloxy!moiety! (showing!one! signal!usually!around!6T7!
ppm).! The! aminoacyl! phosphoramidate! would! then! require! another! enzyme,! a!
phosphoramidase,!to!finally!release!the!monophosphorylated!NA.!






new! signal!was! observed,! so! the! sample!was! left! incubating! at! 25! ˚C! for! a! longer!
period.!After!48!h,!a!small!conversion!of!the!compound!was!seen!by!the!emergence!
of!a!small!new!signal!at!6.00!ppm.!The!sample!was!incubated!up!to!20!days!and!the!






Compound! 5.22! showed! very! poor! biological! activity.! The! results! of! the!
enzymatic!NMR!assay!therefore!indicated!that!this!might!be!due!to!5.22!being!very!
resistant!to!enzymatic!activation.!Following!this,!the!experiment!was!performed!for!
another! EUrd! ProTide,! using! 5!mg! of! compound!5.189which! had! shown!moderate!
activity!in!the!cell!viability!assay.!Figure!5.9!shows!the!main!changes!in!the!31P!NMR!
spectra.!The!blank!sample!shows!the!signals!for!the!mixture!of!diastereoisomers!for!










the! compound! seemed! to! undergo! some! degradation,! as! indicated! by! the!
appearance!of!a!signal!at!T5.57!ppm!(D)!
!!
! These! results! suggested! that! EUrd! ProTides! are! very! resistant! to! the!
activation!by!carboxypeptidase.!
To!verify!if!this!characteristic!is!a!particularity!of!other!3’TethynylTnucleosides,!
the! experiment! was! performed! on! 7!mg! of! the!most! active! EMUrd! ProTide,! 5.29!
(Figure!5.10).!The!blank!experiment!showed!the!signal!of!the!2!diastereoisomers!at!
2.75!and!3.37!ppm.!In!the!next!recorded!experiment,!7!minutes!after!the!addition!of!
the! enzyme,! the! appearance! of! 2! small! signals! at! 3.37! and! 3.84! ppm! (B)! was!





ester!moiety,!which! in! turn!was! transformed! into! the! aminoacyl! phosphoramidate!
from!minute!23!onwards,!showing!a!new!signal!at!6.04!ppm!(C).!After!70!minutes!the!
only!observed!signals!belonged!to!ProTide!5.29!and!its!aminoacyl!phosphoramidate.!





not! processed! at! all! after! the! first! addition! of! the! carboxypeptidase! –! apart! from!
potential!experimental!error!of!course,!but!that!seemed!unlikely!as!the!same!effects!
were!observed!in!two!independent!experiments.!However,!after!the!second!addition!
of! the! enzyme,! some! quantity! of! compounds! 5.18! and! 5.22! underwent! a! slow!
activation.!That!activation!eventually!stopped!and!the!rest!of!the!ProTide!remained!





ProTide!5.189with!medium! activity! in! the! cell! viability! assay! and! the! ProTide!5.229
with!low!activity.!
The!experiment!with!the!EMUrd!ProTide!5.29!showed!the!same!metabolism!
pattern! as! the! EUrd! ProTides! after! the! second! addition! of! the! enzyme.! As! the!
experiment! was! recorded! every! 15.7! minutes,! the! slow! transformation! via!














These! experiments! were! performed! in! collaboration! with! Doctor! Salvatore!
Ferla.!!
Molecular!modelling! studies!were! performed! to! gain! understanding! on! the!
ester!hydrolysis!of!the!3’TethynylTnucleosideTProTides!in!the!first!activation!step,!and!
to!predict! the! conversion!of! the!aminoacyl! intermediate! into!3’ethynylTnucleosideT
5’Tmonohosphate!by!HintT1!enzyme!
Docking9with9cathepsin9A9
During! the! carboxypeptidase! Y! enzymatic! assay! a! slow!hydrolysis! of! the!3’T






Due! to! the! sterical! hindrance! of! the! 3’! ethynyl! group! none! of! the! docking!
poses! fitted! into! the! receptor! in! an! adequate!manner.! Figure!5.11! shows! the!best!
















The! final! step! to! release! of! the!monophosphorylated!NA! inside! the! cells! is!
catalysed! by! Human! triad! nucleotideTbinding! proteins! (Hint).! They! are! responsible!
for! breaking! the! PTN! bond! between! the! aminoacyl! residue! and! the! phosphate! by!
interaction! of! histidine! residues! in! the! active! site.! Residues! His112,! His114! and!
Ser107!are!responsible!for!the!activity.42!
Docking!studies!with!the!aminoacyl!phosphoramidate!analogue!of!EUrd,!ECyd!
and! EMUrd!were! carried! out! on! human!HintT1,! available! in! the! protein! data! bank!
(PDB! 1KPF)43! coTcrystallised!with! a!molecule! of! AMP! (yellow).! The! docking! results!
showed!the!phosphate!moiety!of! the!aminoacyl! intermediate!of!EUrd! in!a! suitable!
position!for!the!cleavage!of!the!PTN!bond.!Moreover,!the!phosphate!and!the!pyridine!
base!lie!in!the!binding!pocket!in!a!similar!manner!to!the!phosphate!and!adenine!of!
the! coTcrystallised! AMP.! The! best! docking! pose! of! the! aminoacyl! intermediates! of!
ECyd!and!EMUrd!do!not!lie!in!a!similar!position!to!AMP!as!EUrd,!but!the!phosphate!
group! lies! in! proximity! of! the! histidine! residues! responsible! for! the! activity.! The!























optimisation! of! the! reported! synthesis! by! Nomura! et# al.! (2002)! was! achieved,!
specifically,!by!changing!the!oxidising!conditions!by!using!DMP!to!obtain!compound!
5.6.! The! second! pathway! explored! delivered! EUrd! in! a! 3Tfold! increased! yield! in!
comparison! to! the! first! one.! ECyd! was! also! synthesised! with! the! optimised!
conditions.! Furthermore,! EMUrd! was! synthesised! for! the! first! time! using!
intermediate!5.13.!!
A!small!family!of!EUrd,!ECyd,!and!EMUrd!ProTides!was!then!synthesised!using!
the! NMI! approach,! although! only! low! reactivity! of! the! coupling! reaction! was!
observed.!In!particular,!ECyd!coupling!reaction!delivered!yields!of!1!–!2%.!A!different!
method!to!synthesise!ECyd!ProTides!using!tBuMgBr!did!not!prove!successful.!







the! inactive! parent! nucleoside! into! a! partially! active! compound.! The! most! active!
ProTides! in! each! family! bore! hexyl,L,AlaTphenyl! substituents! and! showed! a! high!
degree!of!lipophilicity.!
Carboxypeptidase! assays! performed! on! compounds! 5.18,! 5.22! and! 5.29!
showed!very! low!activation!by! this!enzyme.!These! results!may!correspond! to! their!
low!observed! in#vitro!activity!compared!with!the!activity!of!the!parent!nucleosides.!
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3,N4"Etheno"gemcitabine9 ProTides9 –9 Rationale9 behind9 the9
design9
This! novel! nucleoside! analogue! is! a! fusion! between! the! anticancer! drug!
gemcitabine! 6.11! and! 3,N4Tethenodeoxycytidine! 6.3,! a! fluorescent! nucleoside!
analogue,2!which! forms!a!highly!mutagenic!DNA!adduct.3! It!has!not!been! reported!
that!3,N4TethenoTgemcitabine!6.4!was!synthesised!previously.!
!
Gemcitabine! 6.1! is! broadly! used! as! an! anticancer! agent.! It! is! the! first! line!
treatment! for! pancreatic! adenocarcinoma,! but! it! is! also! used! for! the! treatment! of!
breast,!bladder!and!nonTsmall!cell! lung!cancers.4!Gemcitabine!6.1!acts!as!a!prodrug!
that! needs! to! reach! its! diphosphate! (GemTDP)! or! triphosphate! (GemTTP)! forms! in!
order!to!exert!its!biological!actions.!The!major!mechanism!of!action!of!gemcitabine!is!
the! inhibition! of! DNA! synthesis! by! acting! as! a! masked! chain! terminator.! Once!






DP! also! plays! an! important! role:! by! directly! inhibiting! ribonucleoside! reductase! it!
inhibits! the! conversion! from! nucleotide! diphosphate! to! deoxynucleotide!








































low! permeability! of! the! drug,! which! can! be! either! due! to! a! lowly! vascularised!
environment!of!the!tumour,!like!in!the!case!of!pancreatic!cancer,!or!due!to!a!reduced!




resistance! of! cancer! cells! to! gemcitabine.! The! increase! of! cytidine! deaminase! is!
especially! noteworthy! because! they! transform! gemcitabine! into! 2’,2’T
difluorodeoxyuridine! (dFdU),! a! toxic!metabolite! that! acts! by! inhibiting! thymidylate!
synthase.7! Finally,! 5’Tnucleotidases! can! be! overexpressed! as! well.! These! enzymes!
cleave! the! phosphate! from! the! 5'! monophosphate! end! of! the! sugar! moiety! of!
gemcitabine1.!





thus!does!not! release! the! toxic!metabolite.9!Clinical! trials!are! showing! response! to!
the!treatment!with!NUCT1031!in!patients!who!exhibit! low!expression!of!hENT1!and!
deoxycytidine! kinase,! and! high! expression! of! cytidine! deaminase.! Treatment! with!
NUCT1031! led! to!disease!control! in!patients!with! refractory! to! relapsed!cancers!on!
prior!chemotherapy,!including!gemcitabine.10!





the! amino! group! at! position! 4! and! the! nitrogen! atom!at! position! 3.! They! are!well!
known! for! their! promutagenic! effects.! Certain! endogenous! compounds! formed! as!
lipid!peroxidation!byproducts,!and!some!chemical!carcinogens! like!vinyl!chloride!or!
ethyl! carbamate! (metabolised! to! 2Tchloracetaldehyde! and! vinyl! carbamate!
respectively)! can!act! as!nucleic! acid! adducts! generating!etheno!bases! in!both!RNA!
and!DNA.!Etheno!adducts!are!among!the!most!abundant!DNA!adducts!found!in!the!
human!genome.!3,!11!
When! εdC! 6.3! is! incorporated! into! DNA! it! causes! DNA! lesions! which! may!
cause!mutagenic!transitions!and!initiate!malignant!transformations.2!εdC!6.3!causes!
specific! miscoding! by! pairing! with! thymine! instead! of! guanine.12! Cells! have!
mechanisms! for! selfTrepair! and! some!of! the! εdC!6.3! can! be! exised! from! the!DNA,!
probably! by! thymineTDNATglycosylase.3! Mutations! occurring! in! the! RNA! can! also!
have! serious! implications:! if! they! are! present! in! mRNA,! they! can! lead! to!







nucleosides,! nucleotides! and! nucleic! acids.15,16! εdC! 6.3! in! methanol! shows! a!
maximum!emission!wavelength!at!335!nm!and!a!maximum!excitation!wavelength!of!
272! nm.! In! these! conditions,! the! fluorescence! quantum! yield! is! 0.055.16! εdC! 6.3!
shows! a! maximum! emission! wavelength! at! 347! nm! and! a! maximum! excitation!
wavelength!of!300!nm.14!It!was!discovered!that!the!fluorescence!emission!intensity!
of!these!compounds!varies!depending!on!the!pH,!having!a!greater!intensity!at!lower!
pH! values.14! Indeed,! studies! shown! the! need! for! the! nitrogen! at! position! 1! to! be!
protonated!in!order!to!produced!fluorescence.!Figure!6.1!shows!the!intensity!of!the!
fluorescence!of!εC!6.2!at!different!values!of!pH!as!measured!by!Barrio!et#al.!(1976).!






The! objective! of! this! chapter! was! to! create! a! new! nucleoside! analogue! by!
combining! the! sugar!moiety!of!gemcitabine!6.1! and!3,N4Tethenocytosine!as!a!base!
leading!to!3,N4Tethenogemcitabine!6.4.!These!two!compounds!both!interact!with!the!

















synthesis.! The! desired! compound! is! expected! to! react! similarly! to! εdC!6.3,! so! the!
synthesis! of! εdC! 6.39 by! Li! et# al.! (2002)! was! chosen! as! a! reference! point! (Scheme!
6.2),16!aiming!to!extrapolate!the!method!to!synthesise!3,N4TethenoTgemcitabine!6.4.!
It! is! reported! that! the! sugar!has! little! influence!on! the! reactivity!of! this! reaction.18!












6.4! by! two! oneTproton! doublets! at! 7.85! ppm! (HT3)! and! 7.42! ppm! (HT2)! and! their!
vicinal!coupling!constant!of!1.5!Hz.!The!assignment!of! the! lowTfield!signal! to!HT3! is!
based!on!the!inductive!effect!of!NT4!(enhanced!by!the!conjugation!with!the!carbonyl!















































Scheme! 6.4! summarises! the! mechanism! for! this! reaction.! Reported!
investigations! on! the! formation! of! the! ethenoTbridge! resulted! in! the! isolation! of!
intermediate!C.21!Therefore,!the!primary!amine!at!position!4!reacts!with!the!carbonyl!
group! and! the! lone! electron! pair! of! NT1! attacks! the! chloromethylene! moiety.!
However,! there! is! some! controversy! regarding! the! order! in! which! this! reaction!
occurs.!It!was!postulated!that!depending!on!the!specific!reagent!used,!either!NT1!or!
the! amine! at! position! 4,! would! react! first.! Halohaldehyde! reagents! such! as!
chloracetaldehyde!supposedly!react!preferentially!first!with!the!amine,!according!to!
pathway!A!in!Scheme!6.4.18!A!final!dehydration!of! intermediate!C!then!delivers!the!






















































6.4: R = H
6.1: R = F
6.3: R = H






was! preferred! to! synthesise! a! small! family! of! six! ProTides! of! 3,N4TethenoT
gemcitabine,!aiming!to!achieve!5’TProTides!only!(Scheme!6.5).!The!use!of!a!Grignard!
reagent!would! require! the! selective! protection!of! position! 3´! as! established! in! the!



















Compound! 6.11! delivered! a!mixture! of! four! isomers! corresponding! to! two!
diastereoisomers! for! LTAlanine! and! two!diastereoisomers! for!DTAlanine.! This! could!










31P! NMR! spectra! for! the! mixture! after! purification! by! flash! column!
chromatography! and! preparative! TLC! (Figure! 6.4)! showed! 5! signals:! 3.88! and! 3.77!
ppm! are! the! singlets! for! the! 2! diastereoisomers! of! the! predominant! LTAlanine!



































Ethenonucleosides! are! generally! not! very! stable.! They! may! suffer! ring!
opening!in!strong!basic!conditions22!and!indeed,!to!build!a!ProTide!basic!conditions!
have! to! be! used.! This! may! result! in! lower! yields! due! to! degradation.! A! different!
method!to!avoid!ring!opening!is!therefore!to!build!the!ethenoTbridge!directly!onto!a!
gemcitabine! ProTide.! Since! the! reaction! conditions! to! synthesise! 3,N4TethenoT
gemcitabine!are!mild!and!the!reaction!delivered!high!yields,!exploring!the!possibility!














synthesis! of! 3,N4TethenoTgemcitabine! were! then! applied,! while! the! pH! of! the!
reaction!was! slightly! raised! to! 5.! This! reaction! yielded! 61!%,! which! demonstrated!


















































Leukaemia! Pancreas! Colon! Liver! Breast! H&N!
! MOLTT4!! MiaTPaTCaT2! HT29! HepG2! MCFT7! Cal!27!
EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%!
εGem99 1.1! 87! 3.2! 98! 15.3! 90! 5.7! 88! 4.8! 76! 5.1! 94!
Gemcitabine9 -! -! <0.1! 80! 2.2! 57! 52.0! 50! >198! 51! -! !
!
3,N4TEthenoTGemcitabine!6.4!showed!high!top!inhibition.!Inhibition!values!at!
198! µM! were! above! 85! %! except! for! MCFT7! where! it! only! achieved! 76.25! %!
cytotoxicity.! The! EC50! values! were! below! 6! µM! except! for! HT29! where! the! EC50!
reached! 15.34! µM.! 3,N4TethenoTgemcitabine! 6.4! showed! higher! activity! than!
Gemcitabine! 6.1! in! cell! lines! HepG2! (10! times! improvement)! and! MCFT7! where!
gemcitabine! 6.1! displayed! low! activity! and! 3,N4TethenoTgemcitabine! 6.4! is!
moderately!active.!In!MiaTPaTCaT2!and!HT29!cell!lines!gemcitabine!6.1!!(first!line!drug!
for! the! treatment! of! advanced! (nonTresectable! Stage! II! or! Stage! III)! or! metastatic!
(Stage!IV)!adenocarcinoma!of!the!pancreas)4!showed!a!better!activity!profile.!
Table96.5:9Cytotoxic!activity!of!3,N4TethenoTgemcitabine!and!ProTides!against!selected!cancer!cell!lines9
Leukaemia! Pancreas! Colon! Liver! Breast! H&N!
MOLTT4!! MiaTPaTCaT2! HT29! HepG2! MCFT7! Cal!27!
EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%! EC50! TI!%!
εGem9! 1.1! 87! 3.2! 98! 15.3! 90! 5.7! 88! 4.8! 76! 5.1! 94!
6.7! 18.7! 107! 14.2! 100! 40.7! 98! 24.8! 98! 20.4! 99! 3.8! 89!
6.9! 41.6! 94! 59.2! 90! 77.6! 78! 52.2! 93! 56.6! 83! 64.4! 91!
6.11! 18.8! 110! 27.7! 100! 53.8! 103! 37.5! 99! 34.0! 100! 18.7! 99!
6.6! 0.5! 79! 2.6! 76! 65.3! 91! 7.9! 56! 2.1! 61! 1.1! 78!
6.8! 5.7! 101! 4.7! 100! 45.4! 92! 7.8! 79! 8.5! 97! 3.4! 89!
6.10! 10.7! 106! 21.5! 99! 83.3! 93! 43.2! 88! 29.9! 93! 6.3! 84!





ProTides! exhibited! high! top! inhibition! percentages,!most! often! above! 85%.!
Surprisingly! compound!6.69 (NeopTLTAlaTNaph,! LogP!=! 5.26)! showed! the! lowest! top!
inhibition!values,!but!was!the!most!active!compound!in!terms!of!EC50!along!with!6.89
(BzTLTAlaTPh,!LogP!=!4.32).!Both!ProTides!bear!very!different!moieties,!but!they!are!
















would!not!be! a!wise! strategy.!Also! it! is! possible! that! 3,N4TEthenoTGemcitabine!6.49









6.89with! high! activity! in! the! series9were! tested! in! a! carboxypeptidase! Y! enzymatic!
assay! (Table# 6.6).! This! assay! aimed! to! analyse! if! the! different! performance! of! the!
ProTides!is!related!to!any!difference!in!the!first!activation!step!of!the!prodrug!and!if!
3,N4TethenoTgemcitabine! ProTides! can! be! processed! by! the! enzyme! that! was!







The! experiment! was! performed! as! described! in! Chapter! 3! and! the!
experimental! section,! by! dissolving! the! compound! in! deuterated! acetone! and!
recording! the! blank! reference! spectrum.! After! the! addition! of! the! enzyme! to! the!
sample! in! TRIZMA! buffer! at! pH! 7.6! and! 25! ˚C! 31P! NMR! spectra! was! recorded!
periodically!for!13!hours.!Shifts!in!the!signal!indicate!the!formation!of!new!species.!!
As!previously!mentioned,!two!intermediate!compounds!are!often!observed!in!





This! experiment! was! first! performed! with! 5! mg! of! 6.79 (Figure! 6.8).! In! the!
blank! sample! containing! the! mixture! of! diastereoisomers! the! 31P! NMR! spectrum!












The! same! experiment! was! then! performed! using! 5! mg! of! compound! 6.8!
(Figure! 6.9)! in! order! to! determine! if! the! behaviour! of! 6.7! was! shared! among! the!
family!of!3,N4TethenoTgemcitabine!ProTides.!The! first! 31P!NMR!experiment! showed!
two! signals! in! the! spectrum! at! 3.51! and! 3.31! ppm! corresponding! to! the! ProTide.!











donated! by! Doctor! Magdalena! Slusarczyk,! reproducing! the! exact! same! conditions!
and! in! parallel! to! the! experiment! with! compound! 6.8.! NUC! 1031! is! known! to! be!
processed! in! this! experiment.9! A! 31P! NMR! spectrum! was! recorded! for! the! blank!
sample,! after! 15! minutes! of! the! addition! of! the! enzyme! and! 20! hours! after! the!
addition!of! the!enzyme.!Full! conversion!of! the!ProTide!A! (3.53,!3.29!ppm)! into! the!
aminoacyl!intermediate!C!(6.76!ppm)!via!intermediate!B!(4.16!ppm)!was!observed!in!
accordance! with! the! literature.! (Figure! 6.10)! This! validated! the! previously! used!
methods!and!that!the!observed!inertness!of!the!ProTides!6.7!and!6.8!is!likely!to!be!a!















to! characterise! their! fluorescence! was! to! record! the! fluorescence! spectra! of! the!
parent! nucleoside! 6.4! and! ProTide! 6.10.! In! order! to! do! so,! the! compounds! were!
dissolved! in! methanol! at! a! concentration! of! 1! mg/mL.! Fluorescence! was! then!
recorded! by! exciting! the! samples! at! different! wavelengths! until! the! maximum!
excitation! and! emission!wavelengths!were! identified! using! an! Agilent! Cary! Eclipse!
Fluorescence!Spectrophotometer.!
Figure! 6.11! shows! the! absorption! and! emission! spectra! of! the! parent!


















! The!very! similar! fluorescence!profiles! are!probably!due! to! the! fact! that! the!
fluorescence!of!these!molecules!probably!stems!mostly!from!the!bicycle!ring!of!the!
base,!which! is! unaltered! across! the! series.! Because! of! the! low! (“blue”)! absorption!
wavelength! maximum,! these! substances! are! not! ideal! to! be! used! in! fluorescence!
investigations,! because! the! techniques! would! require! a! minimal! excitation!
wavelength!below!350!nm!(which!is!usually!the!lowest!available!wavelength!for!the!
excitation! filters! /! lasers!of! common! research!microscopes).!However! these! values!
could! change! when! the! molecule! interacts! with! the! environment! inside! the! cell.!
Indeed,!fluorophores!are!usually!very!sensitive!to!changes!in!the!environment!and!to!
guest!molecules! and! can! reflect! those! changes! through!measurable! differences! in!
their!fluorescence!spectra.16!
Epifluorescence9microscopy9studies9of9the9solid9compounds9
These! experiments! were! preformed! in! collaboration! with! Professor!Arwyn!
Tomos!Jones!and!Doctor!Jennifer!Mary!Wymant.!!
Before! incubating! cells! with! the! synthesised! compounds,! it! was! worth!
checking! if! the! confocal! microscope! could! detect! the! fluorescence! of! the! solid!
compounds!when! they!were! excited! at! 350! nm.! Therefore,! the! parent! nucleoside!


























Epifluorescence9 microscopy9 studies9 of9 HeLa9 cells9 incubated9 with9 3,N4"etheno"
gemcitabine9and9some9of9its9ProTides9
These! experiments! were! preformed! in! collaboration! with! Doctor! Jennifer!
Mary!Wymant.!
To! monitor! the! fluorescence! of! the! compounds! in! living! cells,! HeLa! cells!
(cervical!cancer)!were!incubated!with!the!parent!nucleoside!6.4!and!ProTides!6.7,!6.8!
and! 6.10! at! 20! µM! for! 15! or! 30! minutes! at! 37! ˚C! prior! to! washing! and! directly!
visualised!on!a!Leica!DMIRB!inverted!epifluorescence!microscope.!
Figure! 6.15! shows! representative! images! from! these! experiments.! The!
control! sample! shows!HeLa!cells!without!being!exposed! to!any!of! the!compounds,!
but!grown!at!the!same!time!and!in!the!same!conditions!as!the!rest!of!the!cells.!They!
show! the! intrinsic! autofluorescence! of! the! cells.! The! comparison! between! the!
autofluorescence!of!the!control!cells!and!the!fluorescence!of!the!cells!incubated!with!




15!minutes! incubation!with! ProTides!6.10,!6.7! and!6.8! and! 30!minutes! incubation!
with!6.89are!shown.!In!summary,!the!cells!that!were!incubated!with!the!compounds!
might!have!emitedt!slightly!more!fluorescence!in!comparison!to!the!control!cells,!but!
the! difference! wasnot! clear! enough! to! be! attributed! to! the! compound! or! to!
variations! in! autofluorescence! of! each! sample.! No! difference! in! fluorescence! was!
observed!between!the!parent!nucleoside!and!the!ProTides,!or!among!the!different!
ProTides.!No!clear!difference!was!also!observed!when!incubating!the!cells!with!the!
compounds! for! a! longer! period.! In! conclusion,! this! experiment! suggests! that! the!

























synthesis! of! ProTides.! A! second! pathway! to! obtain! 3,N4TethenoTgemcitabine!






and! MCFT7.! ProTides! 6.6! and! 6.89 tended! to! retain! the! activity! of! the! parent!
nucleoside.! However,! no! advantage! on! the! use! of! the! ProTide! approach! was!
observed.!Slow!activation!as!a!possible!explanation!for!the!poor!activity!of!the!3,N4T
ethenoTgemcitabine! ProTides! was! proved! by! Carboxypeptidase! Y! assays.! The!
experiment!performed!in!compounds!6.7!and!6.8!showed!that!the!enzyme!could!not!
remove!the!ester!moiety!to!initiate!the!activation!process.!Other!explanation!for!the!
activity!observations! is! that! the!3,N4TethenoTgemcitabine!6.4! can!exert! cytotoxicity!
independently!of!its!phosphate!form.!It!is!also!possible!that!it!exerts!cytotoxicity!in!a!





6.49 and! 6.109 revealed! that! these! compounds! emit! some! dim! fluorescence.!
Incubation! of! HeLa! cells! with! compounds! 6.4,! 6.7,! 6.89 and! 6.10! did! not! show! an!















Primary! Substrate! for! Escherichia! Coli! DoubleTStranded! UracilTDNA!
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Design,! synthesis,! and! evaluation! of! different! families! of! ProTides! were!
reported! in! this! thesis.! They! were! applied! to! 2Tchlorocordycepin,! to! 3’ethynylT
nucleosides!(ECyd,!EUrd!and!EMUrd),!and!to!3,N4TethenoTgemcitabine.!
The! synthesis! of! these! ProTide! families! aimed! to! improve! the! anticancer!
activity! of! the! parent! nucleosides,! and! 2Tchlorocordycepin! and! 3’TethynylT5T
methyluridine! ProTides! showed! a! clear! improvement! in! activity! compared! to! their!
respective! parent! nucleosides.! These! encouraging! results! for! 2Tchlorocordycepin!




downregulation! of! the! first! phosphorylation! step.! Therefore,! the! lower! anticancer!





The! new! synthesised! nucleoside! 3,N4TethenoTgemcitabine! showed!
anticancer! activity.! The! synthesised! ProTides! displayed! lower! or! similar! activity!
compared!to!their!parent!nucleoside.!Here,!no!activation!by!carboxypeptidase!Y!was!
observed.!Because!this!is!a!novel!NA,!the!mechanism!of!its!cytotoxic!activity!remains!
yet! to!be!explored.!Multiple!explanations!are!possible! for! this!behaviour,! including!
the! proven! nonTactivation! of! the! ProTide! by! the! usual! activating! enzymes,! the!








However,! they! also! stress! the! point! that! applying! the! ProTide! approach! does! not!






The!encouraging! results!of! the!2Tchlorocordycepin!ProTides!warrant! further!
biological! testing! and! lead! optimisation.! Future! in! vitro! testing! of! the!
phosphorodiamidate! and! phosphonodiamidate! compounds! of! 2Tchlorocordycepin!
will! then! unveil! if! those! new! strategies! can! successfully! deliver! more! resistant!
monophosphorylated!species,!and!more!active!prodrugs.!!
Further! studies! on! the! slow! activation! of! the! 3’Tethynyl! nucleoside! family!
should! deliver! useful! knowledge! on! the! practicability! for! applying! the! ProTide!
approach.!The!exploration!of!other!pronucleotide!forms!of!this!family!than!ProTides,!
which! successfully! release! the! monophosphorylated! NA,! would! be! of! interest! to!
enhance! the! activity! of! ECyd! and! EUrd,! since! their! ProTides! did! not! boost! their!
activity.!
The!synthesis!of! the!hydrochloride!salt!of!3,N4TethenoTgemcitabine!and!the!
subsequent! synthesis!of! its!ProTides! should!be! investigated! in!order! to! see! if! their!
fluorescence! can!be!enhanced!and! therefore!make! the! visualisation!of!drug! traffic!










All! solvents! were! anhydrous! and! used! as! supplied! by! SigmaTAldrich.! All!
commercially! available! were! used! without! further! purification! and! bought! from!













High! performance! Liquid! Chromatography! (HPLC)! analytical! and! semiT




Proton! (1H),! carbon! (13C),! phosphorus! (31P)! and! fluorine! (19F)! NMR! spectra!




frequencies! of! 500,! 125,! 202,! and! 470! MHz.! Spectra! were! autoTcalibrated! to! the!
deuterated! solvent! peak! and! all! 13C! NMR! and! 31P! NMR! were! protonTdecoupled.!
Chemical!shifts! (δ)!are!given! in!parts!per!million!(ppm)!and!coupling!constant! (J)! in!
Hertz! (Hz).! The! NMR! signals! are! assigned! for! each! molecule! using! the! following!
abbreviations:! singlet),! br! s! (broad! singlet),! d! (doublet),! dd! (doublet! of! doublet),! t!
(triplet)!m,!(multiplet)!











units! of! enzyme! 0.15!mL! of! TRIZMA! buffer! and! stored! at! T20! ˚C.The! experiments!
were! performed! by! dissolving! 3T7! mg! of! the! appropriate! ProTide! in! 200! μl! of!
deuterated! acetone! and!400!μl! of! TRIZMA!buffer! (pH!7.6).! A! 31P!NMR!experiment!













Cell! viability! assays! were! performed! by! WuXi! AppTec.! All! the! compounds!
were!diluted!by!DMSO!to!their!stock!concentrations,!and!kept!in!T80!degree!freezer.!
The! compounds! concentration! starts! at! the! calculated! concentrations,! 3.16Tfold!
dilution!in!DMSO,!9!doses.!For!the!compounds,!the!high!concentration!was!198!μM,!
the! low! concentration! was! 0.0199! μM.! While! for! the! reference! compound!
(Paclitaxel)! the! high! concentration!was! 0.5!μM,! the! low! concentration!was! 0.0001!








All! molecular! modelling! studies! were! performed! on! a! Viglen! Genie!
Intel®CoreTM! i7T3770! vPro! CPU@! 3.40! GHz! x! 8! running! Ubuntu! 14.04.! Molecular!
Operating! Environment! (MOE)! 2015.101! and! PLANTS2! were! used! as! molecular!
modelling!software.!!The!human!HINTT1!and!the!monomeric!serine!carboxypeptidase!
from!Saccharomyces!cerevisiae!strucures!were!downloaded!from!the!PDB!data!bank!
(http://www.rcsb.org/;!PDB! code! 1KPF! and! 1YSC).! Hydrogen! atoms!were! added! to!
the! proteins,! using! the! Protonate! 3D! routine! of! the! Molecular! Operating!
Environment!(MOE).!Ligand!structures!were!built!with!MOE!and!minimized!using!the!
MMFF94x!force!field!until!a!RMSD!gradient!of!0.05!kcal!mol−1/Å−1!was!reached.!The!






for! carboxypeptidase],! binding! site_radius! 12;! cluster! algorithm:! cluster_rmsd! 2.0,!
cluster_strucures!10;!scoring!function:!chemplp.!The!best!10!docking!poses!for!each!




incubated!under! tissue!culture! for!16T20!h.!The!cells!were! then!washed! two! times!
with! DTMEM! phenol! redTfree! medium! (clear! medium)! and! incubated! for! 15T30!
minutes!at!37!˚C!with!clear!medium!containing!20!µM!solution!of!the!compound!to!











stirred! solution! is! heated! at! reflux! temperature! overnight! using! Dean! Stark!







1!eq!of! the!appropriate!amino!acid!ester! is!dissolved! in!dichloromethane! in!
anhydrous! conditions! and! under! Ar! atmosphere.! 1! eq! of! the! appropriate!
phosphorodichloridate! is! carefully! added! to! the! stirring! solution.! Then! the!
temperature!of!the!mixture!is!lowered!at!T78!°C!and!2!eq!of!triethylamine!are!added!




a! quick! chromatographic! column! (CC)! using! hexane/ethylacetate! 1:! 1! as! eluent!






the! mixture! is! warmed! at! 30! ˚C! to! improve! the! solubility.! After! 30! minutes! the!
appropriate! phosphorochloridate! is! added! to! the! mixture! dissolved! in! THF.! The!
reaction!is!kept!between!15!h!to!72!h!monitoring!the!formation!of!the!desired!specie!
by!TLC.!Solvent!is!evaporated!under!reduced!pressure.!When!specified,!the!crude!is!





and! under! Ar! atmosphere.! 1! eq! of! tertTbutyl!magnesium! chloride! is! added! to! the!
stirred!solution.!After!30!minutes!the!appropriate!phosphorochloridate! is!added!to!

















Toluene! sulphonic! acid!monohydrate! suspended! in! 50!ml! of! toluene.! The! reaction!









The! compound!was! prepared! according! the! general! procedure,! using! 5.05! g! of! LT
Alanine!(56.7!mmol);!31.27!mL!of!hexanol!(850.8!mmol)!and!10.79!g!(56.7!mmol)!of!
pTToluene!sulphonic!acid!monohydrate!suspended!in!60!ml!of!toluene.!The!reaction!






Ar),!4.22T4.31! (m,!2H,!OCH2(CH2)4CH3),!4.10! (q,! J#=!7.5!Hz,!1H,!CHCH3),!2.39! (s,!3H,!
CH3TTsOT),!1.69T1.74!(m,!2H,!OCH2CH2CH2CH2CH2CH3),!1.55!(d,!J#=!7.5!Hz,!3H,!CHCH3),!
1.35T1.45!(m,!6H,!OCH2CH2CH2CH2CH2CH3),!0.94!(t,!J#=7!Hz,!3H,!O(CH2)5CH3).!!






The! compound!was! prepared! according! the! general! procedure,! using! 4.89! g! of! LT
Alanine!(54.9!mmol);!40!mL!of!cyclohexanol!(384.3mmol)!and!10.43!g!!(54.9!mmol)!






13C9 NMR9 (1269MHz,9 CDCl3):9 δC! 169.27! (C=O),! 141.51! (CTAr),! 140.34! (CTAr),! 128.82!









The! compound!was! prepared! according! the! general! procedure,! using! 10.0! g! of! LT
Alanine!(112!mmol);!128!mL!of!2Tisopropanol!(1.68!mol)!and!21.3!g!!(112!mmol)!of!pT
Toluene!sulphonic!acid!monohydrate!suspending!in!100!ml!of!toluene.!The!reaction!













process! was! repeated! for! ten! times,! and! then! water! was! evaporated! under! high!
pressure!to!give!3.2!g!of!a!fine!white!powder!were!obtained.!(Yield!15!%)!
1H9NMR9(5009MHz,9CDCl3):9δH!8.17!(br!s!3H,!NH3),!7.76!(d,!J#=!8.2!Hz,!2H,!HTAr),!7.16!
(d,! J# =! 8.2! Hz,! 2H,!HTAr),! 4.08! (q,! J# =! 7.2! Hz,! 1H,! CHCH3),! 4.00! (q,! J# =! 7.1! Hz! 2H,!























It!was!monitored!by! 31P!NMR.!After!90!minutes!stirring!at!RT! the! formation!of! the!
product! was! observed.! The! mixture! was! filtered! and! the! solvent! was! evaporated!
under!reduced!pressure!and!Argon!atmosphere!to!give!us!8.90!g!of!brown!oil!(34.09!














The! compound!was! prepared! according! the! general! procedure,! using! 3.02! g! of! LT
alanine!neopentyl!ester!pTtoluenesulphonate!salt!2.1!(9.1!mmol)!dissolved!in!25!mL!
of! anhydrous! dichloromethane,! 2.38! g! of! naphtyl! phosphorodichloridate! 2.6! (9.1!
mmol)!dissolved!in!5!mL!(2!x!2.5!ml)!of!anhydrous!dichloromethane,!and!2.5!mL!of!

























alanine! ester! chlorinated! salt! (13! mmol)! dissolved! in! 12! mL! of! anhydrous!
dichloromethane,!3.40!g!of!naphtyl!phosphorodichloridate!2.6! (13!mmol)!dissolved!










The! compound!was! prepared! according! the! general! procedure,! using! 1.81! g! of! LT





dissolved! in! 5! mL! (2! x! 2.5! ml)! of! anhydrous! dichloromethane,! and! 2.46! mL! of!




1H9NMR9 (5009MHz,9 CDCl3):9δH!7.31T8.09! (m,!7H,!NaphH),!4.60! (br!s,!1H,!NH),!4.11T






The! compound!was! prepared! according! the! general! procedure,! using! 5.15! g! of! LT
alanine!cyclohexyl!ester!pTtoluenesulphonate!salt!2.3! (15!mmol)!dissolved!in!20!mL!
of! anhydrous! dichloromethane,! 3.92! g! of! naphtyl! phosphorodichloridate! 2.6(15!
mmol)!dissolved!in!5!mL!(2!x!2.5!ml)!of!anhydrous!dichloromethane,!and!4.2!mL!of!













neopentyl! ester! pTtoluenesulphonate! salt! 2.1! (15.1! mmol)! dissolved! in! 40! mL! of!
anhydrous!dichloromethane,!2.26!mL!of!phenyl!dichlorophosphate!(15.1!mmol)!and!
4.2!mL!of!triethylamine!(30.2!mmol).!The!desired!product!was!formed!after!4!hours!
at! RT.! Compound! was! purified! by! chromatographic! column! according! to! the!
protocol.!3.9g!of!a!colourless!oil!were!obtained.!(Yield!77!%).!
31P9NMR9(92029MHz,9CD3OD):9δH!7.64,!7.98.!
1H9 NMR9 (5009MHz,9 CDCl3):9 δH! 7.24T7.42! (m,! 5H,! ArTH),! 4.20T4.30! (m,! 1H,! CHCH3),!






alanine! ester! tosylated! salt! (8.5! mmol)! dissolved! in! 20! mL! of! anhydrous!
dichloromethane,!1.27!mL!of!phenyl!dichlorophosphate!(8.5!mmol)!and!2.34!mL!of!


















alanine! ester! chlorinated! salt! (13! mmol)! dissolved! in! 20! mL! of! anhydrous!
dichloromethane,! 4.8!mL! of! phenyl! dichlorophosphate! (31.9!mmol)! and! 8.9!mL! of!










The! compound!was! prepared! according! the! general! procedure,! using! 6.85! g! of! LT
Alaninie!hexyl!ester!pTtoluenesulphonate!salt!2.2!salt!(20.7!mmol)!dissolved!in!60!mL!
of! anhydrous! dichloromethane,! 3.1! mL! of! phenyl! dichlorophosphate! (20.7! mmol)!

















hours!at!RT.!Compound!was!purified!by! chromatographic! column!according! to! the!
protocol.!5.6!g!of!colourless!oil!was!obtained.!(Yield!77!%).!
31P9NMR9(2029MHz,9CD3OD):9δH!8.03,!7.71.!
1H9 NMR9 (5009 MHz,9 CDCl3):9 δH! 7.23T7.40! (m,! 5H,! ArTH),! 4.15T4.24! (m,! 3H,! CHCH3;!





The! compound!was! prepared! according! the! general! procedure,! using! 5.06! g! (14.7!
mmol)!of!LTalanine!cyclohexyl!ester!pTtoluenesulphonate! salt!2.3! and!2.20!mL!g!of!


























The! compound! was! prepared! according! the! general! procedure,! using! 6.0! g! of! LT
Alanine!isopropyl!ester!pTtoluenesulphonate!salt!2.4!(19.7!mmol)!dissolved!in!50!mL!
of! anhydrous! dichloromethane,! 2.9! mL! of! phenyl! dichlorophosphate! (19.7! mmol)!
and!5.5!mL!of! triethylamine! (39.5!mmol).! The!desired!product!was! formed!after!4!












of! anhydrous! dichloromethane,! 0.5! mL! of! phenyl! dichlorophosphate! (3.36! mmol)!
and!0.94!mL!of!triethylamine!(6.72!mmol).!The!desired!product!was!formed!after!2!




4.29! (m,! 1H,! CHCH3),! 4.08T4.13! (m,! 2H,! OCH2(CH2)6CH3),! 1.53T1.61! (m,! 2H,!
















anhydrous! conditions! and! under! argon! atmosphere.! 2.98! mL! of! a! solution!
acetonitile/water!9:1!(16.6!mmol!of!water)!were!added!to!the!stirring!solution.!9.7!
ml!of!αTacetoxyisobutiryl!bromide!were!added!dropwise!to!the!stirring!solution.!The!






dissolved! in!300!ml!of!dry!methanol,!and!150!ml!of! IRN!78! (OHT)!were!added.!The!
mixture!was!stirring!for!3!hours!and!then!filtered!and!redissolving!in!methanol!and!
filtrate!again!to!recover!the!final!product.!Two!filtrations!were!needed.!Solvent!was!















2.18!mg!of!3.6! (7.68!mmol)!were! suspended! in! 3!ml!of!DMSO!and!5!ml!of! THF! in!







solid! was! suspended! in! 500!ml! of! diethylether! and! stirred! overnight.! Solvent! was!
removed! by! decantation,! and! the! solid! was! dried! evaporating! under! reduced!
pressure.! A! salt! was! formed.! It! was! purified! by! filtering! twice! in! silica! in!






8),! 119.56! (CT5),! 93.58! (CHT1’),! 82.80! (CHT4’),! 76.81! (CHT2’),! 64.01! (CH2T5’),! 34.33!
(CH2T3’).!!
MS9(ES+)9m/z:!Found:!286.1![M!+!H+],!C10H12ClN5O3!required:!652.16![M];!!









The! compound!was!prepared!according! the! general! procedure!A,! using!150!mg!of!
3.2!(0.52!mmol)!dissolved!in!10!ml!of!THF,!0.2!ml!of!NMI!(2.62!mmol)!and!604!mg!of!








2"Chloro"3’deoxyadenosine9 5’"O"[1"naphtyl9 (benzyl"L"alaninyl)]9 phosphate9 (3.10)9
(NMI)9
!
Compound! was! prepared! according! to! the! general! procedure! A! from! 2TchloroT3’T
deoxyadenosine!3.2! (100!mg,!0.35!mmol),!NTmethylimidazole! (140!µL,! 1.75!mmol)!









3H,! Ar),! 7.14T7.43! (m,! 9H,! Ar),! 5.81T5.80! (m,! 1H,! H1’),! 4.97T4.89! (m,! 2H,! OCH2Ph)!
4.53T4.49!(m,!2H,!H4’,!H2’),!4.30T4.35!(m,!1H,!H5’),!4.15T4.21!(m,!1H,!H5’),!3.87T3.95!
(m,! 1H,! CHCH3),! 2.12T2.23! (m,! 1H,! H3’),! 1.86T1.93! (m,! 1H,! H3’),! 1.14T1.17! (m,! 3H,!
CHCH3).!
13C9NMR9(1259MHz,9CD3OD):9δC!174.85!(d!3JCP!=!4.0!Hz,!C=O),!174.55!(d!3JCP!=!4.3!Hz,!
C=O),! 158.07,!158.04! (C6),! 155.31,!155.28! (C2),! 151.34,!151.31! (C4),! 149.69! (CTAr),!
147.96! (d! 2JCP!=!7.25!Hz,!CTipso!Naph),!147.90! (d! 2JCP=!7.0!Hz,!CTipso!Naph),!140.70!
(C8),!137.21,!137.16!(CTipso!OCH2Ph),!136.26!(CTAr),!130.92,!130.80!(CHTAr),!129.56,!




76.54! (C2’),! 68.74! (d! 2JCP=! 5.3! Hz,! C5’),! 68.54! (d! 2JCP=! 5.1! Hz,! C5’),! 67.93,! 67.90!
















product! was! formed! after! 5! days! stirring! at! RT.! After! flash! chromatography! and!
preparative!TLC,!5!mg!of!a!mixture!containing!the!desired!compound!were!obtained,!
but!further!purification!was!unable.!
1H9 NMR9 (5009 MHz,9 CD3OD):9 δH! 1.03T1.06! (m,! 3H,! OCH2CH3),! 1.48T1.53! (m,! 3H,!
CHCH3),!2.52T2.57!(m,!1H,!HHT3’),!2.66T2.77!(m,!1H,!HHT3’),!3.57T3.561(m,!1H,!HHT5’),!























deoxyadenosine!3.2! (350!mg,!1.25!mmol),!NTmethylimidazole! (490!µL,! 6.15!mmol)!
and! naphtyl(2,2TdimethylpropoxyTLTalaninyl)! phosphorochloridate! 2.7! (1416! mg,!





1H,! Naph),! 7.86T7.89! (m,! 1H,! Naph),! 7.69T7.70! (m,! 1H,! Naph),! 7.54T7.46! (m,! 3H,!
Naph),!7.37T7.41!(m,!1H,!Naph),!5.95!(d!J#=!2,!0.5H,!H1’),!5.94!(d!J#=!1.5,!0.5H,!H1’),!







































and! phenyl(2,2TdimethylpropoxyTLTalaninyl)! phosphorochloridate! 2.12! (1231! mg,!
3.69! mmol).! Purification! by! flash! column! chromatography! (eluent! system!
CH3OH/CH2Cl2! 2:98! to! 20:80! over! 14! CV)! and! preparative! TLC! (1000! µm,! eluent!
O



















4.60! (m,! 2H,!H4’and!H2’),! 4.34T4.38! (m,! 0.5H,!H5’),! 4.27T4.31! (m,! 0.5H,!H5’),! 4.16T
4.23! (m,!1H,!H5’),!3.80T3.90! (m,!1H,!CHCH3),!3.57T3.73! (m,!2!H!OCH2C(CH3)3),!2.18T
2.28! (m,! 1H,!H3’),! 1.94T1.99! (m,! 1H,!H3’),! 1.20T1.24! (m,! 3H,!CHCH3),! 0.81! (s,! 4.5!H!
OCH2(CH3)3),!0.79!(s,!4.5!H!OCH2C(CH3)3).!
13C9NMR9(1259MHz,9CD3OD):9δC9175.09!(d!3JCP!=!4.75!Hz,!C=O),!174.909(d!3JCP!=!5.37!




C4’),! 80.659 (d! 3J! =! 8.25!Hz,! C4’),! 76.70,! 76.67! (C2’),! 75.43,! (OCH2C(CH3)3),! 68.68! (d!














The! title! compound! was! prepared! according! to! the! general! procedure! A! using! 2T
chloroT3’Tdeoxyadenosine!3.2!(288!mg,!1.01!mmol),!NTmethylimidazole!(0.4!mL,!5.05!
mmol)! and! hexyl(2,2TdimethylpropoxyTLTalaninyl)! phosphorochloridate! 2.15! (702.5!
mg,! 2.02! mmol).! Purification! by! flash! column! chromatography! (eluent! system!











C=O),! 156.78,! 156.66! (C6),! 153.86,! 153.82! (C2),! 150.69! (d! 2JCP=! 6.3! Hz,! CTipso! Ph),!
150.68!(d!2JCP=!6.3!Hz,!CTipso!Ph),!149.82,!149.77!(C4),!139.32,!139.28!(C8),!129.38,!
129.35!(CHTAr!x!2),!124.76,!124.74!(CHTAr),!120.07!(d!3JCP!=!4.81!Hz,!CHTAr),!119.98!(d!
3JCP! =! 4.66! Hz,! CHTAr),! 118.08,! 118.04! (C5),! 92.06,! 91.90! (C1’),! 79.33,! 79.269 (C4’),!
























The! title! compound! was! prepared! according! to! the! general! procedure! A! using! 2T
chloroT3’Tdeoxyadenosine!3.2!(339!mg,!1.18!mmol),!NTmethylimidazole!(0.47!mL,!5.9!
mmol)!and!octyl(2,2TdimethylpropoxyTLTalaninyl)!phosphorochloridate!2.18!(891!mg,!
2.32! mmol).! Purification! by! flash! column! chromatography! (eluent! system!







4.34! (m,! 1H,!H5’),! 3.99T4.08! (m,! 2H,!OCH2(CH2)6CH3),! 3.91T3.96! (m,! 0.5H!OCHCH3),!
3.86T3.91!(m,!0.5H!OCHCH3),!2.31T2.38!(m,!1H,!H3’),!2.07T2.11!(m,!1H,!H3’),!1.53T1.61!
(m,! 2H,! ! OCH2CH2(CH2)3CH3),! 1.18T1.33! (m,! 13H,! CHCH3,! OCH2CH2(CH2)5CH3),! 0.88T
0.90!!(m,!3H,!OCH2CH2(CH2)5CH3).!
13C9NMR9(1259MHz,9CD3OD):9δC9173.75!(d!3JCP!=!4.6!Hz,!C=O),!173.579(d!3JCP!=!5.8!Hz,!
















3JCP! =! 4.76! Hz,! CHTAr),! 118.07,! 118.03! (C5),! 92.10,! 92.02! (C1’),! 79.34,! 79.289 (C4’),!




MS9 (ES+)9 m/z:! Found:! 726.1! [M! +! H+],! 748.1! [M! +! Na+]! C27H38ClN6O7P! required:!
625.06![M].!






Compound! was! prepared! according! to! the! general! procedure! B! using! 2T
chlorocordycepin!3.2!(200!mg!0.7!mmol),!tertTbutyl!magnesium!chloride!1M!(0.7!ml,!
0.74!mmol)!and!Phenyl(isopropoxyTLTalaninyl)!phosphorochloridate!2.8!(565!mg!1.40!
mmol).! Purification!by! flash! column!chromatography! (eluent! system!CH3OH/CH2Cl2!
2:98! to! 10:90! over! 15! CV)! and! preparative! TLC! (1000! µm,! eluent! system!


























Compound! was! prepared! according! to! the! general! procedure! B! using! 2T
chlorocordycepin!3.2! (211!mg!0.74!mmol),!tertTbutyl!magnesium!chloride!1M!(0.74!
ml,! 0.74!mmol)! and! Naphtyl(isopropoxyTLTalaninyl)! phosphorochloridate! 2.13! (495!
mg! 1.47! mmol).! Purification! by! flash! column! chromatography! (eluent! system!






















































































530!mg! (1.32!mmol)! of! 3.24,! 398!mg! (2.64!mmol)! of! TBDMSCl! and! 359!mg! (5.28!
mmol)! of! imidazole!were! dissolved! in! 2!ml! of! DMF! under! Argon! atmosphere.! The!






























HT3’),! 0.82! (s,! 9H,! (CH3)3TCTSiO(2’)T(CH3)2),! 0.79! (s,! 9H,! (CH3)3TCTSiO(5’)T(CH3)2),! 0.06!




3’),! 26.03! (CH3! x! 3! (CH3)3TCTSiO(2’)T(CH3)2),! 25.74! ! (CH3! x! 3! (CH3)3TCTSiO(5’)T(CH3)2),!







































Compound! was! prepared! according! to! the! general! procedure! B! using! 2’TOT(tertT
butyldimethylsilyl)T2TchloroT3’Tdeoxyadenosine! 3.19! (91! mg! 0.23! mmol),! tertTbutyl!
magnesium! chloride! 1M! (0.23! ml,! 0.23! mmol)! and! Naphtyl(benzyloxyTLTalaninyl)!





























137.14! (CTipso!OCH2Ph),! 136.28,!136.26! (CTAr),! 129.54,!129.52! (CHTAr! x!2),! 129.28,!
129.24! (CHTAr),!129.22,!129.18! (CHTAr!x!2),!128.90,!128.82! (CHTAr),!127.93,!127.88!
(CTAr),!127.76!(d!3JCP!=!5.8!Hz,!CHTAr),!127.48!(d!3JCP!=!8!Hz,!CHTAr),!126.50!(CHTAr),!
126.00!(CHTAr),!122.78,!122.63!(CHTAr),!119.46,!119.44!(C5),!116.36!(d,!4JCP!=!2.9,!CHT
Ar),! 116.19! (d,! 4JCP! =! 3.0,! CHTAr),! 93.32! (CHT1’),! 80.32,! 80.26! (CHT4’),! 77.82,! 77.76!
(CHT2’),!68.79!(d!2JCP=!5.3!Hz,!C5’),!68.65!(d!2JCP=!5.2!Hz,!C5’),!67.95,!67.91!(CH2Ph),!
51.87,!51.74!(CHCH3),!35.56,!35.29!(CH2T3’),!26.23!(CH3!x!3!(CH3)3TCTSiOT(CH3)2),!20.43!























magnesium! chloride! 1M! (0.51! ml,! 0.51! mmol)! and! Phenyl(benzyloxyTLTalaninyl)!
phosphorochloridate! 2.14! (348! mg! 1.02! mmol).! Purification! by! flash! column!





(m,! 0.5H,! H5’),! 4.30T4.34! (m,! 0.5H,! H5’),! 4.17T4.23! (m,! 1H,! H5’),! 3.93T4.02! (m,! 2H,!
OCH2CH3),!3.76T3.84!(m,!1H,!CHCH3),!2.10T2.19!(m,!1H,!H3’),!1.88T1.94!(m,!1H,!H3’),!







(204!mg!0.52!mmol),! tertTbutyl!magnesium! chloride! 1M! (0.52!ml,! 0.52!mmol)! and!
phosphorochloridate! 2.15! (348! mg! 1.02! mmol).! Purification! by! flash! column!
chromatography!(eluent!system!CH3OH/CH2Cl2!1:99!to!8:92!over!14!CV)!afforded!the!













































The! title! compound! was! obtained! by! dissolving! 2’TOT(tertTbutyldimethylsilyl)T2T
chloroT3’deoxyadenosineT5’TOT[1Tnaphtyl! (benzylTLTalaninyl)]! phosphate! 3.20! (90!
mg,!0.12!mmol)! in!2!ml!of!an!aqueous!solution!of!THF/H2O/TFA!1/1/1!at!0! ˚C.!The!
mixture!was!stirred!at!RT!for!25!h.!Solvent!was!evaporated!under!reduced!pressure.!




3H,! Ar),! 7.14T7.43! (m,! 9H,! Ar),! 5.81T5.80! (m,! 1H,! H1’),! 4.97T4.89! (m,! 2H,! OCH2Ph)!
4.53T4.49!(m,!2H,!H4’,!H2’),!4.30T4.35!(m,!1H,!H5’),!4.15T4.21!(m,!1H,!H5’),!3.87T3.95!






C=O),! 158.07,!158.04! (C6),! 155.31,!155.28! (C2),! 151.34,!151.31! (C4),! 149.69! (CTAr),!
147.96! (d! 2JCP!=!7.25!Hz,!CTipso!Naph),!147.90! (d! 2JCP=!7.0!Hz,!CTipso!Naph),!140.70!
(C8),!137.21,!137.16!(CTipso!OCH2Ph),!136.26!(CTAr),!130.92,!130.80!(CHTAr),!129.56,!




76.54! (C2’),! 68.74! (d! 2JCP=! 5.3! Hz,! C5’),! 68.54! (d! 2JCP=! 5.1! Hz,! C5’),! 67.93,! 67.90!









The! title! compound! was! obtained! by! dissolving! 2’TOT(tertTbutyldimethylsilyl)T2T
chloroT3’deoxyadenosineT5’TOT[1Tphenyl(ethylTLTalaninyl)]phosphate! 3.21! (93! mg,!
0.14! mmol)! in! 2! ml! of! an! aqueous! solution! of! THF/H2O/TFA! 1/1/1! at! 0! ˚C.! The!
mixture!was!stirred!at!RT!for!25!h.!Solvent!was!evaporated!under!reduced!pressure.!




















4.62! (m,! 2H,!H4’and!H2’),! 4.34T4.38! (m,! 0.5H,!H5’),! 4.28T4.32! (m,! 0.5H,!H5’),! 4.16T
4.22!(m,!1H,!H5’),!3.93T4.03!(m,!2H,!OCH2CH3),!3.70T3.84!(m,!1H,!CHCH3),!2.20T2.28!
(m,! 1H,! H3’),! 1.95T1.99! (m,! 1H,! H3’),! 1.15T1.21! (m,! 3H,! CHCH3),! 1.06T1.11! (m,! 3H,!
OCH2CH3).!
13C9NMR9(1259MHz,9CD3OD):9δC9173.66!(d!3JCP!=!4.5!Hz,!C=O),!173.659(d!3JCP!=!5.3!Hz,!
C=O),! 156.68,! 156.70! (C6),! 153.93,! 153.88! (C2),! 150.72! (d! 2JCP=! 6.7! Hz,! CTipso! Ph),!
150.71! (d! 2JCP=!6.5!Hz,!CTipso!Ph),!149.89,!149.94! (C4),!139.41,!139.35! (C8),!129.33!
(CHTAr!x!2),!124.74,!124.73!(CHTAr),!120.03!(d!3JCP!=!4.75!Hz,!CHTAr),!119.97!(d!3JCP!=!



















Purification! by! flash! chromatography! (eluent! system! from! CH2Cl2/MeOH! 100:0! to!







































To!a! stirring! suspension!of! compound!3.2! (102!mg,!0.36!mmol)!and! triethyl! amine!
(0.06!ml,!0.43!mmol)!in!anhydrous!THF!(5!ml),!POCl3!(0.04!ml!0.43!mmol)!was!added!
dropwise!at!T78!˚C.!The!mixture!was!allowed!to!slowly!reach!RT!and!it!was!stirred!for!
one! hour.! The! formation! of! the! intermediate! was! monitored! by! 31P! NMR.! A!
suspension!of!LTAlanine!benzyl!ester!pTtoluenesulphonate!salt!(632!mg,!1.8!mmol)!in!
DCM! (5! ml)! was! added! to! the! stirring! mixture.! Temperature! of! the! reaction! was!
lowered!at!T78!˚C!and!TEA!(0.50!ml,!3.6!mmol)!was!added!dropwise!to!the!mixture.!
After! stirring! for! 20! h! at! RT!H2O! (3ml)!was! added! to! the!mixture! and! the! desired!
compound! was! extracted! with! DCM.! The! organic! was! dried! over! Na2SO4! and!





























Ar),! 127.94! (CHTAr),! 127.89! (CHTAr),! 127.87! (CHTAr),! 127.81! (CHTAr),! 119.73! (C5),!










To! a! stirring! suspension! of! compound! 3.2! (121! mg,! 0.42! mmol)! in!
trimethylphosphate!(1!ml),!POCl3!(0.04!ml!0.43!mmol)!was!added!dropwise!at!T5!˚C.!
The!mixture!was!allowed! to! slowly! reach!RT!and! it!was! stirred! for! four!hours.!The!
formation!of!the!intermediate!was!monitored!by!31P!NMR.!A!suspension!of!LTAlanine!




in! H2O! (3ml)!was! added! to! the!mixture! and! the! desired! compound!was! extracted!
with! DCM.! The! organic! was! dried! over! Na2SO4! and! evaporated! under! reduced!














































ml)! and! dried! over! MgSO4,! filtered! and! solvent! was! evaporated! under! reduced!
pressure! and! purification! by! flash! chromatography! (eluent! system! from!





N(COOC(CH3)3)2)! 0.81! (s,! 9H,! (CH3)3TCTSiO(2’)T(CH3)2),! 0.79! (s,! 9H,! (CH3)3TCTSiO(5’)T
(CH3)2),!0.01!(s,!3H,!(CH3)3TCTSiO(2’)T(CH3)2),!0.00!(s,!6H,!(CH3)3TCTSiO(5’)T(CH3)2),!T0.01!
(s,!3H,!(CH3)3TCTSiO(2’)T(CH3)2).!
13C9 NMR9 (1269 MHz,9 CDCl3):9 δC! 153.83! (CT6),! 152.32! (N(COOC(CH3)3),! 150.68!
(N(COOC(CH3)3),!149.83! (CT2),!149.82! (CT4),!144.83! (CHT8),!128.01! (CT5),!92.21! (CHT
1’),!84.24!(N(COOC(CH3)3)2),!81.76!(CHT4’),!77.35!(CHT2’),!63.48!(CH2T5’),!33.19!(CH2T
3’),! 26.67! (N(COOC(CH3)3)2)! 25.28! (CH3! x! 3! (CH3)3TCTSiO(5’)T(CH3)2),! 24.93! (CH3! x! 3!


































18H,! N(COOC(CH3)3)2)! 0.86! (s,! 9H,! (CH3)3TCTSiO(2’)T(CH3)2),! 0.00! (s,! 3H,! (CH3)3TCT
SiO(2’)T(CH3)2),!T0.09!(s,!3H,!(CH3)3TCTSiO(2’)T(CH3)2).!
13C9 NMR9 (1269 MHz,9 CDCl3):9 δC! 153.92! (CT6),! 152.37! (N(COOC(CH3)3),! 150.37!



























minutes! at! 80! ˚C.! Then! the! temperature! of! the! reaction!was! lowered! at! 0˚C,! was!
stirred!for!30!minutes,!and!solvent!evaporated.!The!residue!was!dissolved!in!THF!and!
filtrated.! The!precipitate!was!dried!under!high! vacuum! for! an!hour! generating! the!
aldehyde! 4.59 which! formation! was! monitored! by! 31P! NMR.! The! aldehyde! was!
suspended! without! further! purification! in! 10! ml! of! THF! at! 0! ˚C! under! argon!





the! residue! was! purified! by! flash! chromatography! (eluent! system! from!






















OCH2CH3! x! 2),! 0.78! (s,! 9H,! (CH3)3TCTSiO(2’)T(CH3)2),! 0.04! (s,! 3H,! (CH3)3TCTSiO(2’)T
(CH3)2),!0.00!(s,!3H,!(CH3)3TCTSiO(2’)T(CH3)2).!




OCH2CH3),! 38.76! (CH2T3’),! 28.08! (N(COOC(CH3)3)2)! 25.65! (CH3! x! 3! (CH3)3TCTSiO(2’)T
(CH3)2),!17.91!(C,!(CH3)3TCTSiO(2’)T(CH3)2),!16.38!(d,!3JCP!=!5.52!OCH2CH3),!16.34!(d,!3JCP!
=!5.16!OCH2CH3)!T4.75,!T5.02,!(CH3,!(CH3)3TCTSiO(2’)T(CH3)2).!








was!added.! The!mixture!was! stirring! for!2!h,! filtrated!on!a! short!pad!of! celite! and!






























Compound! 4.7! (1.76! mg,! 0.24! mmol)! was! dissolved! in! 15! ml! of! a! solution!
H2O/HCOOH/THF!1:2:1.! The! solution!was! stirring! for! 72!h! at! RT.! The! solution!was!




























under!argon!atmosphere,!was! redisolved! in!anhydrous! triethylamine! (0.25!ml)!and!
pyridine!(1!ml).!To!this!mixture!LTAlanine!benzyl!ester!pTtoluenesulphonate!salt!(198!




vacuum!and! the! crude!was! purified! by! flash! chromatography! (eluent! system! from!



































To! 500! mg! (2.63! mmol)! of! 1,2TOTisopropylideneTDTxylofuranose! 5.4! dissolved!
dichloromethane!in!anhydrous!conditions!and!Ar!atmosphere,!0.99!ml!(7.15!mmol)!
of!triethylamine!were!added.!The!temperature!of!the!mixture!was!lowered!at!0!°C.!
Then!0.37!ml! (2.89!mmol)!of!4Tchlorobenzoylchloride!were!added!dropwise! to! the!
stirring!mixture.!The!reaction!was!stirring!at!0!°C!for!two!hours.!The!formation!of!the!
product!was!monitored!by!TLC.!16!ml!of!a!saturated!aqueous!NaHCO3!solution!were!








13C9 NMR9 (1269 MHz,9 CDCl3):9 δC! ! 166.47! (C=O),! 140.09! (CTAr),! 131.30! (CH! x! 2! Ar),!













3! h! and! then! after! 15! h.! The! reaction! was! stopped! by! adding! 2Tpropanol! to! the!
mixture!and!stirring!for!10!min!at!RT.!The!mixture!was!partitioned,!the!organic!phase!
washed! with! H2O,! dried! over! MgSO4! and! filtered.! Solvent! was! evaporated! under!








then! it!was! allowed! to! slowly! reach! RT.! After! 24! hours! a! second! addition! of!DMP!
(1.55!g,!3.65!mmol)!was!made!at!0!˚C.!4!hours!later!the!reaction!was!stopped!by!the!
addition! of! 40!ml! of! diethylether.! The!mixture!was!washed!with! 20!ml! of! a! 10!%!
Na2S2O3! solution! in! saturated! NaHCO3.! Then! the! organic! phase! was! washed! with!
brine!and! the!aqueous!phase!extracted!with!diethylether.! The!organic! layers!were!

























under! Ar! atmosphere! CH≡CMgBr! was! added! dropwise! at! 0! ˚C.! After! 1.5! h! full!
conversion!of!the!mixture!was!observed.!Reaction!was!stopped!by!adding!4.8!ml!of!
NH4Cl! aqueous! solution! 15! %,! then,! the! mixture! was! partitioned! and! the! organic!
layer! was! washed! with! 4.8! ml! of! NaCl! 25! %! aqueous! solution.! Solvent! was!
evaporated! under! reduced! pressure! giving! us! a! red! residue.! Purification! by! flash!






13C9 NMR9 (1269 MHz,9 CDCl3):9 δC! 165.55! (C=O),! 139.63! (CTAr),! 131.26! (CH! x! 2! Ar),!


















2.9!ml! of! H2O!were! added.! Reaction!was! stirring! for! 1! h.! Solvent!was! evaporated!

































filtered.! Solvent!was!evaporated!under! reduced!pressure.! The! residue! contained!a!
mixture! of! α! and! β! isomers! in! a! 7:3! ratio.! Isomer! α! was! isolated! by! column!

































A! mixture! of! uracil! (264! mg,! 2.36! mmol)! and! (NH4)2SO4! (10! mg,! 0.08! mmol)! was!
suspended! in! 4.7! ml! (22.42! mmol)! of! HMDS! and! solution! was! warmed! at! reflux!
temperature!(120T130!˚C)!in!anhydrous!conditions!and!under!argon!atmosphere!for!













































102.96! (CHT5),! 89.07! (CHT1’),! 88.35! (CHT4’),! 80.29! (CHT2’,!CH≡CTC3’),! 77.17! (CH≡CT
C3’),!74.26!(CT3’),!63.10!(CH2T5’).!
MS9 (ES+)9m/z:! Found:! 269.1! [M!+!H+],! 291.1! [M!+!Na+]! C17H17ClO6! required:! 268.1!
[M].!!































13C9 NMR9 (1269 MHz,9 CDCl3):! δC! 165.84! (C=O),! 139.89! (CTAr),! 131.57! (CH! x! 2! Ar),!














































To! a! suspension! of! compound! 5.12! (8.15! g,! 21.2! mmol)! and! DMAP! (80! mg,! 0.66!
mmol)!in!80!ml!of!CH2Cl2,!11.8!ml!(84.8!mmol)!of!Et3N!were!added!at!0!˚C!to!give!us!a!
clear! solution.! Then!8.9!ml! (84.8!mmol)! of! 4TClBzCl!were! added.! The! reaction!was!
stirring!for!5!h!at!RT.!Then!20!ml!of!MeOH!and!20!ml!of!CH2Cl2!were!added.!Solution!
was! partitioned! and! organic! layer! washed! with! 20! ml! of! H2O,! 10! ml! of! aqueous!
solution! of!NH4Cl! 15!%! and! 10!mL! of! aqueous! solution! of!NaCl! 25!%.! The! organic!
layer! was! dried! over! Na2SO4! and! filtered.! Solvent! was! evaporated! under! reduced!
pressure!to!give!us!a!brown!oil!that!was!purified!isolated!by!column!chromatography!










CαTOCOCH(CH3)2! ! x!3),!175.64,!175.29,!174.60! (C=O,!CβTOCOCH(CH3)2! ! x!3),!165.84!
(CαTAr),!165.81!(CβTAr),!131.76!(CHαβ!x!2!Ar),!129.39!(CHα!x!2!Ar),!129.32!(CHβ!x!2!














82.6! (CHαT4’),! 79.30! (CHβT2’),! 76.98! (CβT3’),! 76.48! (CαT3’),! 75.87! (CHαT2’),! 65.88!
(CH2βT5’),! 64.74! (CH2αT5’),! 34.70,! 34.64,! 34.44,! (CHα,! OCOCH(CH3)2! x! 3),! 34.58,!
34.21,! 34.43,! (CHβ,! OCOCH(CH3)! 2! x! 3),! ! 19.46,! 19.37,! 19.35,! 19.33,! 19.22.,! 19.17,!









A! mixture! of! uracil! (1.13! g,! 10.1! mmol)! and! (NH4)2SO4! (92! mg,! 0.7! mmol)! was!
suspended! in! 20.1! (95! mmol)! ml! of! HMDS! and! solution! was! warmed! at! reflux!
temperature!(120!˚C)!in!anhydrous!conditions!and!under!argon!atmosphere!for!1!h.!
Solvent! was! evaporated.! To! this! mixture! compound9 5.139 (3.0! g,! 5.0! mmol)! was!
added! dissolved! in! 10! ml! of! ACN.! SnCl4! (0.17! ml,! 1.44! mmol)! was! added! to! the!
stirring!mixture!at!0!˚C.!Next!the!temperature!was!raised!at!30!˚C!and!the!reaction!
was!kept!for!24!h.!Solvent!was!evaporated!and!the!residue!was!partitioned!between!
toluene! and!HCl! 3M.! The! organic! layer!was!washed!with! saturated!NaHCO3,! dried!





















OCOCH(CH3)2! x! 2.)! 1.00T1.05! (m,! 12H,!OCOCH(CH3)2! x2),! 0.00! (s,! 9H,! (CH3)3SiC!≡CT
C3’).!
13C9NMR9(1269MHz,9CD3OH):9δC!175.49,!174.69!(C=O!OCOCH(CH3)2!!x!2)!165.88!(C=O,!
CT4),! 163.54! (C=O,!CT4ClBzO),! 150.82! (C=O,!CT2),! 140.61! (C,! 4ClBzO),! 139.94! (CHT6)!
131.76!(CH!x!2,!4ClBzO),!129.57!(CH!x!2,!4ClBzO),!128.47!(C,!4ClBzO),!104.18!(CHT5),!




























102.96! (CHT5),! 89.07! (CHT1’),! 88.35! (CHT4’),! 80.29! (CHT2’,!CH≡CTC3’),! 77.17! (CH≡CT
C3’),!74.26!(CT3’),!63.10!(CH2T5’).!
MS9 (ES+)9m/z:! Found:! 269.1! [M!+!H+],! 291.1! [M!+!Na+]! C17H17ClO6! required:! 268.1!
[M].!!







Compound! was! prepared! according! to! the! general! procedure! A! using!
3’ethynyluridine!5.1!(158!mg,!0.59!mmol),!NTmethylimidazole!(0.23!mL,!2.95!mmol)!
and!naphtyl(2,2TdimethylpropoxyTLTalaninyl)!phosphorochloridate!2.7!(456!mg,!1.37!



















1H9NMR9 (5009MHz,9 CD3OD):9 δH! 8.06T8.10! (m,!1H,!Naph),!7.77T7.80! (m,!1H,!Naph),!
7.59T7.63! (m,! 1H,! Naph),! 7.55! (d,! J# =! 8.1! Hz,! 0.5H! HT6),! 7.42T7.53! (m,! 4.5H,! HT6,!
Naph),!7.30T7.35!(m,!1H,!Naph),!5.82!(d,!J#=!6.3!Hz,!0.5H,!HT1’),!5.80!(d,!J#=!5.9!Hz,!
0.5H,!HT1’),!5.40!(d,!J#=!8.0!Hz,!0.5H!HT5),!5.39!(d,!J#=!8.0!Hz,!0.5H!HT5),!4.32T4.48!(m,!
2H,! HT5’),! 4.15T4.17! (m,! 0.5H,! HT4’),! 4.10T4.12! (m,! 0.5H,! HT4’),! 4.07! (d,! J#=! 5.9! Hz,!
0.5H,!HT2’),!4.04!(d,!J#=!6.3!Hz,!0.5H,!HT2’),!3.94T4.00!(m,!1H,!CHCH3),!3.65T3.74!(m,!









2’),! 76.77,! 76.51! (CH≡CTC3’),! 74.06,! 73.98! (COOCH2C(CH3)3),! 72.56,! 72.22! (CHT3’),!














Compound! was! prepared! according! to! the! general! procedure! A! using!
3’ethynyluridine!5.1!(100!mg,!0.37!mmol),!NTmethylimidazole!(0.15!mL,!1.85!mmol)!
and!phenyl(2,2TdimethylpropoxyTLTalaninyl)!phosphorochloridate!2.12!(370!mg,!1.11!









4.28T4.43! (m,! 2H,! HT5’),! 4.15T4.18! (m,! 0.5H,! HT4’),! 4.08T4.13! (m,! 1.5H,! HT4’,! HT2’),!
3.88T3.96!(m,!1H,!CHCH3),!3.66T3.78!(m,!2H,!OCH2C(CH3)3),!3.10!(s,!0.5H,!CH≡CTC3’),!





















2’),! 76.77,! 76.51! (CH≡CTC3’),! 74.05,! 74.02! (COOCH2C(CH3)3),! 72.32,! 72.08! (CHT3’),!
66.66! (d! 2JCP=! 5.3!Hz,! CH2T5’),! 66.54! (d! 2JCP=! 5.1!Hz,! CH2T5’),! 50.37,! 50.19! (CHCH3),!








































124.80! (CHTAr),!120.07! (d,! 3JCP!=!4.5,!CH!Ph!x!2),!119.98! (d,! 3JCP!=!4.61,!CH!Ph!x!2),!
101.84,!101.66!(CHT5),!88.00,!87.48!(CHT1’),!84.30!(d!3J!=!8.7!Hz,!C4’),!84.06!(d!3J!=!8.2!
Hz,! C4’),! 80.77,! 80.64! (CH≡CTC3’),! 78.66,! 78.57! (CHT2’),! 76.74,! 76.63! (CH≡CTC3’),!










5.1! (56! mg,! 0.21! mmol)! in! 5! ml! of! TFH,! NMI! (0.1! ml,! 1.2! mmol)! and!
phosphorochloridate!2.14!(604!mg,!1.57!mmol)!dissolved!in!3!ml!of!THF!Solvent!was!
evaporated!and!the!residue!was!partitioned!between!CH2Cl2!and!HCl!0.5M.!After!the!
acidic!workTup! compound!was!detected! in! the!aqueous! layer.!All! the!phases!were!


















Compound! was! prepared! according! to! the! general! procedure! A! using!
3’ethynyluridine!5.1!(100!mg,!0.37!mmol),!NTmethylimidazole!(0.15!mL,!1.86!mmol)!
and! naphthyl(hexyloxyTLTalaninyl)! phosphorochloridate! 2.15! (389!mg,! 1.12!mmol).!
The! reaction!was! stirring! for! 20! h.! Purification! by! column! chromatography! (eluent!








(d,! J# =! 6.4! Hz,! 0.5H,! HT2’),! 3.93T4.02! (m,! 2H,! OCH2(CH2)4CH3),! 3.82T3.90! (m,! 1H,!



































Compound! was! prepared! according! to! the! general! procedure! A! using!
3’ethynyluridine! 5.1! (143!mg,! 0.53! mmol),! NTmethylimidazole! (0.2! mL,! 2.6! mmol)!
and! naphtyl(isopropyloxyTLTalaninyl)! phosphorochloridate! 2.17! (486.04! mg,! 1.59!
mmol).! The! reaction!was! stirring! for! 20! h.! Purification! by! column! chromatography!







4.84T4.89! (m,! 1H,! OCH! (CH3)2),! 4.27T4.41! (m,! 2H,! HT5’),! 4.14T4.16! (m,! 0.5H,! HT4’),!
























Hz,! CH2T5’),! 66.51! (d! 2JCP=! 5.0! Hz,! CH2T5’),! 50.41,! 50.25! (CHCH3),! 20.63,! 20.56!






























and! HCl! 3M.! The! organic! layer! was! washed! with! saturated! NaHCO3,! dried! over!






Hz,!1H!HT5’),! 2.54T2.59! (m,!2H,!OCOCH(CH3)2! x!2)!1.08T1.11! (m,!12H,!OCOCH(CH3)2!
x2),!0.00!(s,!9H,!(CH3)3SiC!≡CTC3’).!
13C9NMR9(1269MHz,9CD3OD):9δC!175.19,!174.31!(C=O!OCOCH(CH3)2!!x!2)!165.04!(C=O,!
CT4),!160.19! (C=O,!CT4ClBzO),!147.60! (C=O,!CT2),!143.44! (CHT6),!139.66! (C,!4ClBzO),!
130.96! (CH! x! 2,! 4ClBzO),! 128.71! (CH! x! 2,! 4ClBzO),! 128.13! (C,! 4ClBzO),! 96.79! (C,!
(CH3)3SiC≡CTC3’),!96.32!(C,!(CH3)3SiC≡CTC3’),!!94.44!(CHT5),!87.83!(CHT1’),!81.69!(CHT



























MS9 (ES+)9m/z:! Found:!268.1! [M!+!H+],!290.1! [M!+!Na+]!C11H13N3O5! required:!267.1!
[M].!






Compound! 5.23! was! prepared! according! to! the! general! procedure! A! using!
3’ethynylcytidine!5.2!(383!mg,!1.43!mmol),!NTmethylimidazole!(0.57!mL,!7.15!mmol)!






































CH3OH/CH2Cl2! from! 3:97! to! 10:90)! and! preparative! TLC! (1000! µm,! eluent! system!






















2H,! OCH2CH2(CH2)3CH3),! 1.25T1.31! (m,! 3H,! CHCH3),! 1.14T1.24! (m,! 6H,!
OCH2CH2(CH2)3CH3),!0.77T0.82!(OCH2CH2(CH2)3CH3).!
13C9NMR9(1259MHz,9CD3OD):!δC!173.88!(d!3JCP!=!4.5!Hz,!COOCH2(CH2)4CH3),!173.49!(d!




















Compound! was! prepared! according! to! the! general! procedure! A! using!
3’ethynylcytosine!5.2! (90!mg,! 0.34!mmol),!NTmethylimidazole! (0.13!mL,! 1.7!mmol)!
and!naphtyl(isopropyloxyTLTalaninyl)!phosphorochloridate!2.17!(311!mg,!1.02!mmol).!





! Compound!5.2! (500!mg,! 1.87!mmol)!was! dissolved! in! dry! acetone! (30!ml).!



































Phenyl(hexyloxyTLTalaninyl)! phosphorochloridate! 2.15! (327! mg! 0.96! mmol).! Then!
























A!mixture! of! thymine! (445!mg,! 3.52!mmol)! and! (NH4)2SO4! (48!mg,! 0.3!mmol)!was!






and! HCl! 3M.! The! organic! layer! was! washed! with! saturated! NaHCO3,! dried! over!



























CT4),! 164.15! (C=O,!CT4ClBzO),! 151.14! (C=O,!CT2),! 140.59! (C,! 4ClBzO),! 135.18! (CHT6)!












for! 2.5! h! at! 40! ˚C.! Then,! 0.6! ml! of! AcOH! glacial! were! added,! and! solvent! was!






































































and! naphthyl(hexyloxyTLTalaninyl)! phosphorochloridate! 2.15! (549!mg,! 1.58!mmol).!
The! reaction!was! stirring! for! 20! h.! Purification! by! column! chromatography! (eluent!
system!CH3OH/CH2Cl2! from!0:100! to! 10:90!over! 20!CV)! and!preparative! TLC! (2000!





4.02! (m,! 3H,!HT2’,!OCH2(CH2)4CH3),! 3.81T3.87! (m,! 1H,! CHCH3),! 3.07! (s,! 0.5H,! CH≡CT















3H,! CH3TCT5),! 1.47T1.53! (m,! 2H,! OCH2CH2(CH2)3CH3),! 47T1.53! (m,! 7H,! CHCH3!
OCH2CH2(CH2)3CH3),!0.77T0.80!(m,!3H,!OCH2CH2(CH2)3CH3).!
13C9NMR9(1259MHz,9CD3OD):9δC!173.76!(d!3JCP!=!3.8!Hz,!COOCH2(CH2)4CH3),!173.51!(d!
3JCP! =! 5.6! Hz,! COOCH2(CH2)4CH3),! 164.92! (C=O,! CT4),! 151.05,! 151.01! (C=O,! CT2),!
150.88!(d!2JCP!=!6.8!Hz,!CTipso!Ph),!150.73!(d!2JCP=!7.2!Hz,!CTipso!Ph),!136.21,!136.15!
(CHT6),!129.44,!129.43!(CHTAr!x!2),!124.90,!124.88!(CHTAr),!120.04!(d,!3JCP!=!4.4,!CH!
Ar!x!2),!120.03! (d,! 3JCP!=!4.4,!CH!Ar!x!2),!110.66,!110.43! (CT5),!85.15! (d! 3J!=!8.3!Hz,!
C4’),!85.04!(d!3J!=!7.0!Hz,!C4’),!85.07,!84.98!(CHT1’),!80.78,!80.66!(CH≡CTC3’),!78.68,!













Compound!was! prepared! according! to! the! general! procedure! A! using! 3’ethynylT5T

















mmol).! The! reaction! was! stirring! for! 20! h.! Purification! by! flash! column!















(d,! 3JCP!=!4.9,!CH!Ph!x!2),!110.32! (CT5),!88.09,!87.62! (CHT1’),!88.85! (d! 3JCP!=!8.9!Hz,!
C4’),!88.74!(d!3JCP!=!8.2!Hz,!C4’),!80.78,!80.65!(CH≡CTC3’),!78.69,!78.62!(CHT2’),!76.77,!
76.51! (CH≡CTC3’),! 74.05,!74.02! (COOCH2C(CH3)3),! 72.32,!72.08! (CT3’),! 66.66! (d! 2JCP=!
5.3! Hz,! CH2T5’),! 66.54! (d! 2JCP=! 5.1! Hz,! CH2T5’),! 50.37,! 50.19! (CHCH3),! 30.94,! 30.93!
















































Hz,! CH2T5’),! 66.51! (d! 3JCP=! 5.0! Hz,! CH2T5’),! 50.41,! 50.25! (CHCH3),! 20.63,! 20.56!










Compound! 5.32! was! prepared! according! to! the! general! procedure! A! using! 3’T
ethynylT5Tmethyluridine96.3!(200!mg,!0.83!mmol),!NTmethylimidazole!(0.33!mL,!4.15!
mmol)! and! phenyl(cyclohexyloxyTLTalaninyl)! phosphorochloridate! 2.16! (614.07!mg,!
1.77! mmol).! The! reaction! was! stirring! for! 20! h.! Purification! by! flash! column!
chromatography!using!Biotage!ZIP!KPTSil!80!g!column!(eluent!system!CH3OH/CH2Cl2!




















HT2’),! 3.91T3.97! (m,!1H,!CHCH3),!3.10! (s,!0.5H,!CH≡CTC3’),!3.08! (s,!0.5H,!CH≡CTC3’),!
1.84! (s,!1.5H,!CH3TCT5),!1.82! (s,!1.5H,!CH3TCT5),!1.78T1.84! (m,!2H,!OCH(CH2)5),!1.68T













To! a! solution! of! 2’TdeoxyTcytidine! (237! mg,! 1.04! mmol)! in! 5! ml! of! H2O! at! 37! ˚C!
Chloracetaldehyde!2!M!was!carefully!added.!pH!was!controlled!by!adding!aqueous!
solution!of!HCl!0.5!M!and!saturated!aqueous!solution!of!NaHCO3!dropwise!to!reach!















































Compound! was! prepared! according! to! the! general! procedure! A! using! 1,! N6T
ethenogemcitabine!6.4!(154!mg,!0.54!mmol),!NTmethylimidazole!(0.2!mL,!2.6!mmol)!
and!naphthyl(2,2TdimethylpropoxyTLTalaninyl)! phosphorochloridate!2.7! (397.23!mg,!



















































Compound! was! prepared! according! to! the! general! procedure! A! using! 1,! N6T
ethenogemcitabine!6.4!(150!mg,!0.52!mmol),!NTmethylimidazole!(0.2!mL,!2.6!mmol)!
and! phenyl(2,2TdimethylpropoxyTLTalaninyl)! phosphorochloridate! 2.12! (520.65! mg,!
1.56! mmol).! The! reaction! was! stirring! for! 22! h.! Purification! by! flash! column!
chromatography!using!Biotage!ZIP!KPTSil!80!g!column!(eluent!system!CH3OH/CH2Cl2!








































Compound! was! prepared! according! to! the! general! procedure! A! using! 1,! N6T
ethenogemcitabine9 6.4! (61!mg,!0.56!mmol),!NTmethylimidazole!(0.2!mL,!2.6!mmol)!




solution!of!HCl! 0.5!M.! Then!evaporated!under! reduced!pressure! and! repurified!by!!







































































7.21,! 1.5H,! CHCH3),! 1.36! (d,! 1.5H,! J# =! 7.16,! 1.5H,! CHCH3),! 1.22T1.26! (m,! 3H,!!
OCH2CH3).!
13C9NMR9(1259MHz,9CD3OD):9δC9173.65!(d!3JCP!=!4.5!Hz,!C=O,!ester),!173.489(d!3JCP!=!


















Compound! was! prepared! according! to! the! general! procedure! A! using! 1,! N6T
ethenogemcitabine96.4!(152!mg,!0.53!mmol),!NTmethylimidazole!(0.2!mL,!2.6!mmol)!
and! phenyl(hexyloxyTLTalaninyl)! phosphorochloridate! 2.15! (427.7! mg,! 1.47! mmol).!
The!reaction!was!stirring!for!32!h.!Purification!by!flash!column!chromatography!using!
Biotage!ZIP!KPTSil!80!g!column!(eluent!system!CH3OH/CH2Cl2!2:98!to!5:95!over!10!CV)!
afforded! a! yellow! oil! that! was! dissolved! in! CH2Cl2! and! washed! with! an! aqueous!
solution!of!HCl! 0.5!M.! Then!evaporated!under! reduced!pressure! and! repurified!by!!










1.65! (m,! 2H,! ! OCH2CH2(CH2)3CH3),! 1.35T1.39! (m,! 3H,! CHCH3),! 1.26T1.39! (m,! 6H,!
OCH2CH2(CH2)3CH3),!0.87T0.90!!(m,!3H,!OCH2CH2(CH2)3CH3).!
13C9NMR9(1259MHz,9CD3OD):9δC9173.73!(d!3JCP!=!4.6!Hz,!C=O,!ester),!173.499(d!3JCP!=!





























Compound! was! prepared! according! to! the! general! procedure! A! using! 1,! N6T
ethenogemcitabine! 6.4! (170! mg,! 0.59! mmol),! NTmethylimidazole! (0.24! mL,! 2.9!
mmol)! and! phenyl(cyclohexyloxyTLTalaninyl)! phosphorochloridate! 2.16! (614.07!mg,!
1.77! mmol).! The! reaction! was! stirring! for! 20! h.! Purification! by! flash! column!
chromatography!using!Biotage!ZIP!KPTSil!80!g!column!(eluent!system!CH3OH/CH2Cl2!
0:100! to! 10:90! over! 20! CV)! and! preparative! TLC! (2000! µm,! eluent! system!
CH3OH/CH2Cl2! 5:95)! afforded! a! mixture! of! D# and! L# ProTides.! Preparative! HPLC!
(H2O/ACN!40:60!isocratic)!and!a!second!Preparative!HPLC!(H2O/ACN!60:40!isocratic)!
isolated! a!mixture! of! diasteroisomers!R! and! S! of! L! Alanine,! and! a! single! L! Alanine!
diasteroisomer.!!!


































1’),! 4.70T4.78! (m,! 1H,!OCH(CH2)5),! 4.42T4.61! (m,! 2H,!HT5’),! 4.33T4.41! (m,! 1H,!HT3’),!
4.17T4.23! (m,! 1H,! HT4’),! 3.94T4.00! (m,! 1H,! CHCH3),! 1.78T1.84! (m,! 2H,! OCH(CH2)5),!











(1)!! Molecular! Operating! Environment! (MOE! 2015.10);! Chemical! Computing!
Group,! Inc.:! Montreal,! Quebec,! Canada;! URL! http://www.chemcomp.com!
(2015).!


















1! 2! 3! 4! 5! 6! 7! 8! 9! 10! 11! 12!
































Compound!2! Dose!1! Dose!2! Dose!3! Dose!4! Dose!5! Dose!6! Dose!7! Dose!8! Dose!9!
E9
F9





























Plate(1( 1! 2! 3! 4! 5! 6! 7! 8! 9! 10! 11! 12!
(
A! !! !! !! !! !! !! !! !! !! !! Max( ((
εGem(( B! !! 2240! 10980! 20940! 32800! 48780! 82800! 81860! 85220! 92760! 91040! !!
( C! !! 2020! 10560! 20480! 31280! 55340! 73200! 88140! 95940! 95940! 96860! !!
6.7( D! !! 340! 21340! 40160! 54540! 78700! 82900! 89420! 90760! 94080! 90480! !!
(
E! !! 420! 22200! 40640! 69960! 85040! 85960! 94180! 105760! 94920! 89540! !!
6.9( F! !! 13540! 43740! 91720! 93500! 90740! 92080! 102300! 99000! 98260! 93300! !!
(
G! !! 13400! 42860! 84200! 92180! 99940! 91740! 101460! 102940! 95520! 92120! !!
(
H! !! !! !! !! !! !! !! !! !! !! !! !!
!
Inhibition!%!
( Plate(1( 1! 2! 3! 4! 5! 6! 7! 8! 9! 10! 11! 12!
! A! !! !! !! !! !! !! !! !! !! !! Max( ((
εGem(! B! !! 97.57!! 88.09!! 77.29!! 64.43!! 47.11!! 10.22!! 11.24!! 7.59!! @0.58!! 1.28!! !!
! C! !! 97.81!! 88.55!! 77.79!! 66.08!! 39.99!! 20.63!! 4.43!! @4.03!! @4.03!! @5.03!! !!
6.7! D! !! 99.63!! 76.86!! 56.45!! 40.86!! 14.66!! 10.11!! 3.04!! 1.59!! @2.01!! 1.89!! !!
! E! !! 99.54!! 75.93!! 55.93!! 24.14!! 7.79!! 6.79!! @2.12!! @14.68!! @2.92!! 2.91!! !!
6.9! F! !! 85.32!! 52.57!! 0.55!! @1.38!! 1.61!! 0.16!! @10.93!! @7.35!! @6.55!! @1.17!! !!
! G! !! 85.47!! 53.53!! 8.70!! 0.05!! @8.37!! 0.52!! @10.02!! @11.62!! @3.57!! 0.11!! !!














































































































εGem! 3.17!! 2.73!! 98.04!! 44.15!! 0.80!! 198!!
6.7! 14.21!! 13.32!! 99.63!! 42.65!! 0.92!! 198!!
6.9! 59.20!! 51.24!! 90.06! 45.06!! 2.20!! 198!!
!
CPF 938
Conc.(µM)
0.1 10
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hi
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Absolute,EC50,(µM), 59.20!!
Relative,EC50,(µM), 51.24!!
Top(%), 90.06!!
Bottom(%), 45.06!!
Slope, 2.20!!
, !
Y?Max, 120!
Y?Min, 420!
Step, 20!
